

DECLARATION

In the matter of U.S. Patent Application Ser. No. 10/070,387 in the name of Naoki MIDOH, et al.

I, Kyoko IMAMURA, of Kyowa Patent and Law Office, 2-3, Marunouchi 3-Chome, Chiyoda-Ku, Tokyo-To, Japan, declare and say:

that I am thoroughly conversant with both the Japanese and English languages; and,

that the attached document represents a true English translation of Japanese Patent Application No. 1999-253040 filed on September 7, 1999.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: October 13, 2004

Kyoko IMAMURA

Name of Document: Patent Application

Reference Number: PM1533

Application Date: September 7, 1999

To: The Commissioner of the Patent Office

International Patent Classification: C12N

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Naoki MIDOH

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Kaoru OKAKURA

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Koichi MIYAMOTO

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Manabu WATANABE

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name: Koji YANAI

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Tetsuya YASUTAKE

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Sato AIHARA

Inventor:

Address: c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Takafumi FUTAMURA

Inventor:

Address: c/o Technische Universitat Berlin,

Max-Volmer-Institut fur Biophysikalische Chemie Und Biochemie, Franklinstr. 29, D-10587 Berlin,

Germany

Name:

Horst Kleinkauf

Inventor:

Address: c/o Pharmac

c/o Pharmaceutical Technology Labs., Meiji Seika

Kaisha, Ltd., 788, Kayama, Odawara-Shi,

Kanagawa-Ken

Name:

Takeshi MURAKAMI

Applicant:

Identification Number: 000006091 Name: MEIJI SEIKA KAISHA, LTD. Representative: Ichiro KITAZATO

Tel.: 03-3273-3357

Indication of the Fee:

Account Number:

008305

Fee:

21,000 Yen

List of Documents filed:

Specification

1 copy

Drawing

1 copy

Proofreading:

Needed

[TITLE OF INVENTION] CYCLIC DEPSIPEPTIDE SYNTHETASE GENE [SCOPE OF CLAIMS]

[Claim 1]

A gene carrying the following DNA (a) or (b):

(a) DNA of a nucleotide sequence shown as SQ ID No. 1; (b) a microorganism-derived DNA hybridizing with the DNA of the nucleotide sequence (a) under stringent conditions and encoding a protein with cyclic depsipeptide synthetase activity.

[Claim 2]

A protein described below in (a) or (b):

- (a) a protein of an amino acid sequence shown as SQ ID No.2; or
- (b) a protein of an amino acid sequence prepared through deletion, substitution or addition of one or several amino acids in the amino acid sequence (a) and with cyclic depsipeptide synthetase activity.

[Claim 3]

A recombinant vector carrying a gene according to claim 1.

[Claim 4]

A microorganism harboring a recombinant vector according to claim 3 and expressing the gene.

[Claim 5]

A microorganism according to claim 4, wherein the microorganism is a fungus producing the substance PF1022.

[Claim 6]

A method for producing the substance PF1022 and a derivative thereof by using a microorganism according to claim $4\ \mathrm{or}\ 5.$

[DETAILED DESCRIPTION OF THE INVENTION]
[0001]

[Technical Field to which the Invention Belongs]

The present invention relates to the cyclic depsipeptide synthetase gene for producing the substance PF1022 as a cyclic depsipeptide with anthelmintic activity, a protein encoded by the gene, a recombinant vector using the gene, and a method for producing the substance PF1022 in a substance PF1022-producing microorganism integrated with the recombinant vector.

[0002]

[Prior Art]

The substance PF1022 [cyclo(D-lactyl-L-Nmethylleucyl-D-3-phenyllactyl-L-N-methylleucyl-D-lactyl-L-N-methylleucyl-D-3-phenyllactyl-L-N-methylleucyl)] cyclic depsipeptide produced by a filamentous fungus of Agonomycetales, namely the strain PF1022 [Mycelia sterilia; the strain was deposited as FERM BP-2671 at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan]. The substance PF1022 exerts an extremely high anthelmintic activity on nematodes parasitic on animals [Japanese Patent publication No. 35796/1991; Sasaki, T. et al., J. Antibiotics., 45, 692 (1992)]. Therefore, the substance is useful as an anthelmintic for animals and is additionally useful as a raw material for the synthesis of a more highly active derivative of the substance. [0003]

The amounts of secondary metabolites produced by microorganisms and separated from natural origins are generally very slight. So as to industrially utilize such metabolites, therefore, the productivity of the secondary metabolites is necessarily increased. For the increase of the productivity, the examination of the culturing methods and the culture medium

components, the modification of the fermentation conditions such as addition of the precursors, and the mutation of the strains by ultraviolet irradiation or mutagen are carried out. In recent years, the productivity has been increased by utilizing gene recombinant technology in addition to the aforementioned methods.

[0004]

As the method, the enhancement of the expression of the genes of enzymes involved in the biosynthetic pathways, the enhancement of the expression of the genes involved in the control of the biosynthesis, and blockage of unnecessary biosynthetic pathways and the like are practically effected [Khetan, A. and Hu, W.-S. Manual of Industrial Microbiology and Biotechnology 2nd edition, p. 717, (1999)]. As a specific example, further, it has been known a method for improving the productivity, comprising allowing the hemoglobin gene of a bacterium to be expressed for the purpose of the improvement of the oxygen usability [Minas, W. et al., Biotechnol. Prog. 14, 561, (1998)].

[0005]

The most general means for the improvement of the productivity by gene recombinant technology is the enhancement of the expression of the genes of enzymes involved in biosynthetic pathway. For the application of the means, essentially, the transformation method of subject microorganism is established; a promoter and a terminator applicable to the enhancement of the expression are to be present; and the biosynthetic pathway is to be elucidated and their genes are to be isolated. The transformation method of a fungus producing the substance PF1022, comprising integrating a foreign gene, has already been established (WO 97/00944); and also, a report concerning the promoter and terminator

applicable to the enhancement of the expression has been issued (Japanese Patent Application No. 252851/1999). However, no gene involved in the biosynthetic pathway has been isolated. [0006]

The substance PF1022 is of a structure comprising L-N-methylleucine, D-lactic acid, and D-phenyllactic acid, which are bonded together through ester bonds and amide bonds. It is considered that the substance is synthesized from 4 molecules of L-leucine, 2 molecules of D-lactic acid and 2 molecules of D-phenyllactic acid by a certain peptide synthetase in a fungus producing the substance. Peptide synthetase means an enzyme involved in the biosynthesis of microbial secondary metabolites, such as peptide, depsipeptide, lipopeptide and peptide lactone, from substrates of amino acids and hydroxy acid. The sequences of some peptide synthetases have already been elucidated [Marahiel, M. A. et al., Chem. Rev., 97, 2651, (1997)]. The reaction with such enzyme is totally different from the synthetic system of protein with ribosome using mRNA as template. Peptide synthetase has one domain for each substrate, where each substrate is activated with ATP for binding through phosphopantothenic acid in the domain; and the resulting bound substrates form amide bonds or ester bonds due to the catalytic actions in the regions between the individual domains.

[0007]

[Problem to be solved by the invention]

The cyclic depsipeptide synthetase gene capable of improving the productivity of the substance PF1022 is provided, by permitting excess expression thereof in a fungus producing the substance PF1022.

[8000]

[Means for Solving the Problem]

So as to overcome the problem, the inventors isolated the cyclic depsipeptide synthetase gene for the synthesis of the substance PF1022 from a fungus producing the substance PF1022, on the basis of the sequence of the conserved region of a known peptide synthetase. Furthermore, the inventors successfully improved the productivity of the substance PF1022 by preparing an expression vector modified with the promoter and terminator of the gene and integrating the expression vector in the fungus producing the substance PF1022. Thus, the invention has been achieved.

[0009]

More specifically, the invention relates to the following aspects.

- 1. A gene carrying the following DNA (a) or (b):
 - (a) DNA of a nucleotide sequence shown as SQ ID No. 1; or
- (b) a microorganism-derived DNA hybridizing with the DNA of the nucleotide sequence (a) under stringent conditions and encoding a protein with cyclic depsipeptide synthetase activity.
- 2. A protein described below in (a) or (b):
- (a) a protein of an amino acid sequence shown as SQ ID No. 2; or
- (b) a protein of an amino acid sequence prepared by deletion, substitution or addition of one or several amino acids in the amino acid sequence (a) and with cyclic depsipeptide synthetase activity.
- 3. A recombinant vector carrying a gene in a first aspect of the invention.
- 4. A microorganism harboring a recombinant vector in a third aspect of the invention and expressing the gene.
- 5. A microorganism in a fourth aspect of the invention, wherein the microorganism is a fungus producing the substance PF1022.

6. A method for producing the substance PF1022 and a derivative thereof by using a microorganism in a fourth or fifth aspect of the invention.

[0010]

[Mode for Carrying out the Invention]

The cyclic depsipeptide synthetase gene of the invention can be isolated from a fungus producing the substance PF1022 for example by the following method.
[0011]

A library comprising the genomic DNA of a fungus producing the substance PF1022 is prepared by extracting the genomic DNA from the fungus producing the substance PF1022, cleaving the DNA with an appropriate restriction endonuclease, and subsequently ligating to a phage vector.

Based on the conserved region of the amino acid sequence of a known peptide synthetase and a partial amino acid sequence of the cyclic peptide synthetase purified from the fungus producing the substance PF1022, an appropriate primer is synthesized, which is used to effect polymerase chain reaction (PCR) with the genomic DNA derived from the fungus producing the substance PF1022 as template, to amplify a DNA fragment of the cyclic peptide synthetase gene. Using the DNA fragment as probe, the genome library is screened. In such manner, the whole region of the cyclic peptide synthetase gene can be isolated. After the determination of the nucleotide sequence of the DNA fragment, appropriate restriction cleavage sites are introduced upstream the translation initiation codon and downstream the translation termination codon by means such as PCR, to recover a gene fragment singly containing the cyclic peptide synthetase gene.

[0012]

The gene of the invention encompasses a nucleotide

sequence hybridizable with the thus determined nucleotide sequence under stringent conditions. Using routine methods (for example site-directed mutagenesis) in the field of genetic engineering, additionally, DNA fragments with modification of the gene, such as addition, insertion, deletion or substitution of the gene, can be encompassed within the scope of the invention. The stringent conditions herein referred to mean that the rinsing procedure of the membrane after hybridization is carried out in solutions at low salt concentrations and high temperature, for example, a condition such that rinsing is effected in 0.2 x SSC (1 x SSC: 15 mM citrate trisodium, 150 mM sodium chloride) - 0.1 % SDS solution at 60°C for 15 minutes.

A promoter is conjugated upstream the cyclic peptide synthetase gene isolated by the method, while a terminator is conjugated downstream the cyclic peptide synthetase gene; additionally, selective marker genes such as nutrient auxotrophic complementary genes or/and genes with chemical resistance are conjugated thereto, to prepare a recombinant vector for gene expression.

The selective markers for use in recombinant vectors for gene expression include for example nutrient auxotrophic complementary genes such as pyrG, argB, trpC, niaD, TRP1, LEU2 and URA3; and genes with chemical resistance against destomycin, benomil, oligomycin, hygromycin, G418, bleomycin, fleomycin, phosphinothricin, ampicillin, and kanamycin.
[0015]

The conjugation of the promoter and terminator to the inventive gene and the insertion thereof into a vector can be carried out by methods known per se. The promoter and terminator for use in accordance with the invention are not

specifically limited, and include for example, genes of glycolytic enzymes, such as 3-phosphoglycerate kinase, glycelaldehyde-3-phosphate dehydrogenase and enolase; genes of amino acid synthesis, such as ornithine carbamoyltransferase and tryptophan synthase; genes of hydrolases, such as amylase, protease, lipase, cellulase and acetoamidase; genes of oxidoreductases, such as nitrate reductase, orotidine-5'-phosphate dehydrogenase, and alcohol dehydrogenase; and genes of bacteria producing the substance PF1022, which are highly expressed in the fungus producing the substance PF1022, such as Abp1.

[0016]

[0017]

The transformation of a host with a recombinant vector prepared in such manner and the culturing of the resulting transformant enable prominent production of the substance PF1022. For a host with no synthesis of \underline{L} -leucine, \underline{D} -lactic acid or \underline{D} -phenyllactic acid as a substrate for the cyclic depsipeptide synthetase of the invention, additionally, the host is cultured after addition of deficient substrates or derivatives thereof, whereby the substance PF1022 or derivatives thereof can be produced. The invention also encompasses the culturing of the transformant in a culture medium to collect the substance PF1022 or a derivative thereof from the resulting microorganisms.

As the host for use, appropriate bacteria or fungal microorganisms usable as hosts for gene recombination can be used, with no specific limitation. Preferably, the host is <u>Escherichia coli</u>, a bacterium of the genus <u>Bacillus</u>, an actinomycetes, yeast and a filamentous fungus; more preferably, the host is a filamentous fungus producing the substance PF1022; and most preferably, the host is the strain PF1022 (Mycelia

sterilia, FERM BP-2671).
[0018]

[0019]

The transformation of such host can be carried out by methods known per se. For example, the introduction of a recombinant vector for gene expression into a host can be carried out by routine methods, for example electroporation process, polyethylene glycol process, Agrobacterium process, lithium process, calcium chloride process and the like, with no specific limitation.

The transformant can also be cultured by general methods, appropriately selecting culture media and culturing conditions and the like. As the culture media, use can be made of routine components, such as carbon sources for example glucose, sucrose, thick malt syrup, dextrin, starch, glycerol, molasses, animal and vegetable oils and the like. As the nitrogen source, additionally, use can be made of soy bean powder, wheat germ, pharmamedia, corn steep liquor, cotton seed bran, meat extract, polypeptone, malt extract, yeast extract, ammonium sulfate, sodium nitrate, urea and the Additionally, it is effective to add inorganic salts capable of generating sodium, potassium, calcium (calcium carbonate and the like), magnesium, cobalt, chloride, phosphorus (dipotassium hydrogen phosphate), sulfuric acid (magnesium sulfate and the like) and other ions, if necessary. necessary, furthermore, selective chemical agents including various vitamins such as thiamine (thiamine chloride salt and the like), amino acids such as glutamic acid (sodium glutamate and the like) and asparagine (DL-asparagine and the like), trace nutrients such as nucleotide and antibiotics can be added. Organic materials and inorganic materials supporting fungal growth and promoting the production of the substance PF1022 or

a derivative thereof can appropriately be added. [0020]

The pH of the culture medium is about pH 6 to pH 8. As the culturing method, agitation culture, aerated agitation culture or submerged aerobic culture under aerobic conditions can be carried out. Particularly, submerged aerated culture is the most appropriate. The temperature appropriate for culturing is 15°C to 40°C. In many cases, the microorganism grows around 26°C to 37°C. The production of the substance PF1022 or a derivative thereof varies, depending on the culture medium and culture conditions or the host used, but the accumulation thereof generally reaches the peak in 2 days to 25 days by any of the culture methods. Just when the amount of the substance PF1022 or a derivative thereof reaches the peak, the culturing is terminated, to isolate and purify the objective substance from the culture.

[0021]

So as to recover the substance PF1022 or a derivative thereof from the culture, general separation means utilizing the characteristic properties, for example solvent extraction method, ion exchange resin method, adsorption or partition column chromatography method, gel filtration method, dialysis method, precipitation method and crystallization method, can be used singly or in appropriate combinations thereof to extract and purify the substance PF1022 or a derivative thereof. From the culture, for example, the substance PF1022 or a derivative thereof is extracted in acetone, methanol, butanol, ethyl acetate, butyl acetate and the like. So as to further purify the substance PF1022 or a derivative thereof, chromatography using Sephadex LH-20 (Pharmacia Co.) or Toyopearl HW-40 (Toso, Co.) is satisfactorily effected. By the methods described above or combinations thereof, the substance PF1022 or a

derivative thereof can be recovered in purity. [0022]

[Examples]

The present invention will now be described in the following examples, but the invention is not limited to them.
[0023]

Example 1

Cloning of cyclic depsipeptide synthetase gene from a fungus producing the substance PF1022

Genomic DNA isolation and preparation of genome library With UV irradiation or NTG treatment, mutation was induced into the fungus (Mycelia sterilia; FERM BP-2671) producing the substance PF1022, to prepare a fungal strain 432-26 producing the substance PF1022 and having an improved productivity of PF1022, from which the genome DNA was extracted. The fungal strain 432-26 producing the substance PF1022 was cultured in 50-m1 of a seed culture medium [1 % yeast extract, 1 % malt extract, 2 % polypeptone, 2.5 % glucose, 0.1 % dipotassium hydrogen phosphate, 0.05 % magnesium sulfate (pH 7.0)] at 26°C for 2 days, to recover the fungi by centrifugation. resulting fungi were frozen in liquid nitrogen and ground in a mortar with a pestle. From the ground fungi, the genome DNA was isolated by ISOPLANT (Nippon Gene, Co.) according to the attached protocol. The isolated genome DNA was partially digested with Sau3A I, to recover DNA fragments of 15 kb to 20 kb by agarose gel electrophoresis, which were then treated with alkali phosphatase to dephosphorylate the termini of the DNA fragments. The DNA fragments were inserted in a phage vector Lambda DASH II (STRATAGENE, CO.). The recombinant phage vector recovered in such manner was subjected to in vitro packaging with Gigapack III Gold Packaging Extract (STRATAGENE CO.) according to the attached protocol. Subsequently,

recombinant phage grew on the host <u>Escherichia coli</u> strain XL1-Blue MRA (P2) for plaque formation on a plate.
[0024]

2. Isolation of partial DNA fragment of cyclic depsipeptide synthetase gene

A known peptide synthetase was subjected to multiple alignment, so that WTSMYDG and VVQYFPT were detected as excellently conserved regions. Based on these sequences, 5'-TGGACIWSNATGTAYGAYGG-3' (SO ID NO. 5'-GTIGGRAARTAYTGIACNAC-3'(SQ ID NO. 4) were synthesized. Using these primers, the genome DNA isolated from the fungus producing the substance PF1022 was used as template for PCR. Using 50 ng of the genome DNA as template, 1 .25 units ExTag DNA polymerase (TaKaRa Brewery, Co.), the attached buffer and dNTP mixture, and 10 µM primer in 50 µl of a reaction solution, PCR was conducted under the following conditions: 94°C for 3 minutes [94°C for one minute, 65°C (with 0.5°C decrement per one cycle) for one minute, 72°C for one minute] x 30 times and 72°C for 3 minutes. Through the reaction, a DNA fragment of about 350 bp was amplified; and the resulting DNA fragment was inserted in pCR2.1 plasmid vector, by using Original TA Cloning Kit (Invitrogen Co.) according to the attached protocol. [0025]

The nucleotide sequence of the thus cloned DNA fragment was determined, by using DNA sequencing Kit dRhodamine Terminator Cycle Sequencing Ready Reaction (Perkin Elmer Co.) and ABI PRISM 310 Genetic Analyzer (Perkin Elmer Co.) according to the attached protocol. Consequently, the nucleotide sequence of the isolated DNA fragment was homologous to the peptide synthetase gene, which apparently indicates that the DNA fragment was a part of the objective cyclic depsipeptide synthetase gene.

[0026]

3. Cloning of the whole region of the cyclic depsipeptide synthetase gene

The probe for use in the screening of the genome library was prepared, by PCR to allow the DNA fragment to incorporate fluorescein-labeled dUTP. By using pCR2.1 plasmid vector inserted with 100 ng of the DNA fragment of the cyclic depsipeptide synthetase gene as template, 1.25 units ExTaq DNA polymerase (TaKaRa Brewery, Co.) and the attached buffer, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.02 mM dTTP, 0.18 mM fluorescein-labeled dUTP (FluoroGreen; Amersham Co.) and 10µM primers (SQ ID Nos. 3 and 4) in 50 µl of a reaction solution, PCR was carried out under the following conditions: 94°C for 2 minutes, (94°C for 30 seconds, 55°C for one minute and 72°C for one minute) x 25 times, 72°C for 3 minutes. Through the reaction, a fluorescein-labeled probe of about 350 bp was prepared.

[0027]

On the plate with formed plaques as prepared in Example 1.1, Hybond-N+ membrane (Amersham Co.) was mounted, to deposit the plaques. The membrane was treated with an alkali, to denature the recombinant phage DNA on the membrane into a single strand and thereby adsorb the DNA on the membrane. The phage DNA-adsorbed membrane was placed in a buffer prepared by using Hybridization Buffer Tablets (Amersham Co.), for incubation at 60°C for one hour. The fluorescein-labeled probe was denatured and added to the resulting incubation mixture, for overnight hybridization at 60°C. Thereafter, the membrane was rinsed in 1 x SSC (SSC: 15 mM citrate trisodium, 150 mM sodium chloride) -0.1 % SDS solution at 60°C for 15 minutes and further rinsed in 0.2 x SSC-0.1 % SDS solution at 60°C for 15 minutes. The

fluorescein-bound plaque was visualized by using DIG-wash and block buffer set (Boehringer Mannheim, Co.), alkali phosphatase-labeled anti-fluorescein antibody (Antifluorescein-AP, Fab fragment, Boehringer Mannheim Co.), a chromogenic substrate nitroblue tetrazolium chloride (Boehringer Mannheim Co.) and X-phosphate (Boehringer Mannheim Co.) according to the attached protocol. In such manner, a positive clone carrying the 5' upstream region and 3' downstream region of a region homologous to the probe was screened. [0028]

4. Determination of the nucleotide sequence The DNA fragment in the positive clone thus isolated was amplified by PCR using primers 5'-GCGGAATTAACCCTCACTAAAGGGAACGAA-3' (SQ ID No. 5) and 5'-GCGTAATACGACTCACTATAGGGCGAAGAA-3' (SQ ID No. 6) as the phage vector sequences. Using 100 ng of the positive clone DNA as template, 2.5 units LA Tag DNA polymerase (TaKaRa Brewery, Co.), the attached buffer and dNTP mixture, 2.5 mM magnesium chloride, and 0.2 µM primer in a reaction solution of 50µl, PCR was effected under the following conditions: 94°C for one minute, (98°C for 10 seconds and 68° C for 15 minutes) x 25 times, 72°C for 15 minutes. The resulting PCR product was purified and treated with a nebulizer, to be decomposed randomly into fragments of 0.5 kb to 2.0 kb. The termini of the resulting fragments were blunt ended with T4 DNA polymerase and phosphorylated with T4 polynucleotide kinase, to be then inserted at the EcoRV site of pT7Blue (Novagen Co.) for insertion in Escherichia coli strain JM109. 168 colonies thus prepared were directly subjected to PCR using M13 Primer M4 (TaKaRa Brewery, Co.) and M13 primer RV (TaKaRa Brewery, Co.) and were then purified, which were then sequenced by using M13 primer M4 (TaKaRa Brewery, Co.). Using 1.25 units ExTaq DNA polymerase (TaKaRa Brewery,

Co.), the attached buffer and dNTP mixture, and 0.5 µM primer, PCR was effected in 50 µl of a reaction solution under the following conditions: 94°C for 4 minutes, (94°C for 30 seconds, 55°C for 30 seconds and 72°C for 2 minutes) x 30 times, 72°C for 3 minutes. Additionally, sequencing was effected, by using DNA Sequencing Kit dRhodamine Terminator Cycle Sequencing Ready Reaction (Perkin Elmer Co.) and ABI PRISM 310 Genetic Analyzer (Perkin Elmer Co.) according to the attached protocol.

Based on the results, an insufficiently analyzed region was amplified by PCR using a primer newly designed on the basis of the analyzed nucleotide sequence and was then purified. Using the primer used for PCR, the region was sequenced, whereby the 15606-bp nucleotide sequence of the DNA fragment in the positive clone was determined.

The analysis of the sequence apparently indicates that an open reading frame (ORF) of 9633 bp was present and a protein speculated from the sequence comprised 3210 amino acid residues of 353 kDa and that the protein was homologous to the peptide synthetase. Additionally, the protein with the highest homology was enniatin synthetase (S39842) with 56 % homology. The nucleotide sequence and amino acid sequence of the ORF of the cyclic depsipeptide synthetase gene thus isolated in accordance with the invention are shown as SQ ID Nos. 1 and 2, respectively in the sequence listing.

Example 2

[0031]

Improvement of PF1022 productivity due to the excess expression of cyclic depsipeptide synthetase gene

 Construction of recombinant vector for gene expression (Figure 1) From the positive clone recovered in Example 1. 3, plasmid pPF7 was prepared by cleaving the inserted DNA fragment with NotI and inserting the DNA fragment into the NotI site of the pBluescriptII KS+ (STRATAGENE CO.). pPF7 was cleaved with BanIII and SmaI and electrophoresed on agarose gel, to recover a DNA fragment of about 8250 by from the agarose gel. The fragment was inserted in pBluescriptII KS+, to prepare plasmid pPF7-1.

[0032]

Using pPF7 5'as template, AGCATCGGATCCTAACAATGGGCGTTGAGCAGCAGCCCTA-3' (SO ID No. 7; designed for the initiation of the translation at the 9th Met from the terminus of the ORF) or 5'-AGCATCGGATCCTAACAATGTCAAACATGGCACCACTCCCTA-3' (SQ ID No. 13; designed for the initiation of the translation at the first Met from the Ν terminus of the ORF), 5'and TTTGCTTCGTACTCGGGTCCT-3'(SQ ID No. 8) as primers for the amplification of a region of about 440 bp (using SQ ID Nos. 7 and 8) or a region of about 470 bp (using SQ ID Nos. 13 and 8) around the Ν terminus to the BanIII site, and 5'-GCATCGCGATACTAGAGAAG-3' (SQ ID No. 9) 5'and AGCATCGAATTCGGATCCCTAAACCAACGCCAAAGCCCGAAT-3' (SQ ID No. 10) as primers for the amplification of a region of about 920 bp from the SmaI site to the C terminus, PCR was effected. the primers were designed so as to insert the BamHI site at the 5' and 3' sites of the inventive cyclic depsipeptide synthetase gene. Using 150 ng of the plasmid DNA as template, 2.5 units KOD DNA polymerase (Toyo Boseki), the attached buffer and dNTP mixture, 1 mM magnesium chloride, and 0.5 µM primer in 50 µl of a reaction solution, PCR was effected under the following conditions: 98°C for 30 seconds, (98°C for 15 seconds, 65°C for 2 seconds, 74°C for 30 seconds) x 10 times, 74°C for one minute.

The PCR reaction solutions recovered by using the individual primers were precipitated with ethanol, to recover PCR products. Concerning the N terminal region, the N terminal region was cleaved with BamHI and BamIIII; concerning the C terminal region, the C terminal region was cleaved with SmaI and BamHI. Thereafter, the resulting fragments were electrophoresed on agarose gel, to recover DNA fragments from the agarose gel. [0033]

The PCR fragment of the C terminal region was inserted in the SmaI and BamHI sites of pPF7-1, to prepare plasmid pPF7-2. plasmid was cleaved with BanIII and BamHI electrophoresed on agarose gel, to recover a DNA fragment of about 9170 bp from the agarose gel. The DNA fragment and the N terminal region prepared by using SQ ID Nos. 7 and 8 were simultaneously inserted in the BamHI site of pBluescript II KS+, to reconstruct the cyclic depsipeptide synthetase gene of the invention and prepare plasmid pPFsyn (initiating translation at the 9th Met from the N terminus of the ORF). [0034]

Alternatively, an about 9170-bp DNA fragment cleaved from pPF7-2 and the N-terminal region prepared by using SQ ID Nos. 7 and 13 were simultaneously inserted in the BamHI site of pHSG299 (TaKaRa Brewery Co.), to reconstruct the cyclic depsipeptide synthetase gene of the invention and prepare plasmid pPFsynN (initiating the translation at the first Met from the N terminus of the ORF). In such manner, the cyclic depsipeptide synthetase gene with the BamHI sites on both the termini was prepared.

[0035]

Herein, <u>Escherichia coli</u> transformed with the plasmid pPFsyn (<u>Escherichia coli</u> DH5α) was deposited with Accession No. FERM P-17541 at National Institute of Bioscience and

Human-Technology, Agency of Industrial Science and Technology, supra.

[0036]

Additionally, Escherichia coli transformed with the plasmid pPFsynN (Escherichia coli DH5 α) was deposited with Accession No. FERM P-17542 at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, supra.

[0037]

pPFsyn or pPFsynN was cleaved with <u>Bam</u>HI. Subsequently, the cyclic depsipeptide synthetase gene region was recovered from the individual gels. The gene region was inserted at the <u>Bam</u>HI site of pABPd with the promoter and terminator of <u>Abpl</u> gene described in Japanese Patent Application No. 252851/1999, to prepare an expression vector pABP/PFsyn (initiating the translation at the 9th Met of the N terminus of ORF) and an expression vector pABP/PFsynN (initiating the translation at the first Met of the N terminus of ORF) as the expression vectors for expressing the cyclic depsipeptide synthetase gene of the invention.

[8800]

2. Introduction and expression of cyclic depsipeptide synthetase gene in fungus producing the substance PF1022
The expression vectors were introduced in a fungus producing the substance PF1022 (Mycelia sterilia; FERM BP-2671) according to the method of Example 1 described in WO 97/00944, to screen strains with high resistance against hygromycin B. The introduction of the objective gene in these strains was confirmed by PCR using a primer 5'-TGATATGCTGGAGCTTCCCT-3' (SQ ID No. 11) prepared from the sequence of Abpl promoter and a primer 5'-GCACAACCTCTTTCCAGGCT-3' (SQ ID No. 12) prepared from the sequence of the cyclic depsipeptide synthetase gene. In

such manner, gene-introduced strains with high resistance against hygromycin B and with the inventive cyclic depsipeptide synthetase gene introduced therein were screened.
[0039]

The gene-introduced strains and the parent strain (Mycelia sterilia; FERM BP-2671) were separately cultured in 50 ml of a seed culture medium at 26°C for 2 days; 1 ml of each of the cultures was inoculated separately in a generation culture medium [6 % thick malt syrup, 2.6 % starch, 2 % wheat germ, 1 % pharmamedia, 0.2 % magnesium sulfate 7 hydrates, 0.2 % calcium carbonate, 0.3 % sodium chloride (pH 7.5)] and cultured therein at 26°C for 4 days. The resulting culture was centrifuged at 4500 rpm for 5 minutes to harvest the fungus; the resulting individual fungus species were rinsed in 0.3 M potassium chloride. The individual fungal species were frozen in liquid nitrogen and freeze-dried.

The following extraction procedure was carried out on ice or in a low-temperature chamber at 4°C. Into a 2-ml tube containing 10 mg of the freeze-dried fungal species and 1.0 ml of glass beads (0.5-mm diameter) was added 1.0 ml of an extraction buffer [50 mM Tris-HC1 (pH 8.0), 0.3 M potassium chloride, 60 % glycerol, 10 mM ethylenediaminetetraacetate disodium, 5 mM dithiothreitol, 10 μM leupeptin, phenylmethanesulfonic acid, 60 µg/ml chimostatin]. microtube was set in a Mini-Bead-Beater-8 (Biospec, Co.), which was then driven at the maximum speed for 3 minutes for extraction. The resulting mixture was centrifuged at 15000 rpm for 5 minutes; 100 µl of the supernatant was charged in and mixed with 100 μ l of 10 % trichloroacetic acid solution. After the solution was left to stand for 15 minutes, the solution was centrifuged at 15000 rpm for 10 minutes. The resulting

precipitate was dissolved in 15 µl of an alkali solution (2 % sodium carbonate, 0.4 % sodium hydroxide), to which was added 60 µl of a sample buffer [125 mM Tris-HC1 (pH 6 . 8), 20 % glycerol, 4 % sodium dodecylsulfate, 10 % 2-mercaptoethanol, 50 mg/1 bromophenol blue]. This was heated in boiling water for 5 minutes, and was then electrophoresed [Sodium Dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)] on 4 % to 20 % polyacrylamide gel with an electrophoresis system (Tefco Co.). The polyacrylamide gel after electrophoresis was stained by using Quick-CBB (Wako Pure Chemical Co.) according to the attached protocol. The electrophoresis result of the proteins extracted from the parent strain and the gene-introduced strain with pABP/PFsyn is shown in Figure 2. [0041]

As described above, the expression level of the cyclic depsipeptide synthetase in the gene-introduced strains was distinctively higher than the level in the parent strain.
[0042]

3. Extraction and assay of the substance PF1022 The gene-introduced strains and the parent strain were separately cultured in 50 ml of a seed culture medium at 26°C for 2 days; and 1 ml of each of 50 ml of the cultures was inoculated separately in a generation culture medium and cultured therein at 26°C for 6 days. 10 ml each of the cultures was placed and centrifuged at 3000 rpm for 10 minutes; and the resulting strains were harvested separately. 10 ml of methanol was added to the individual strains, which were vigorously shaken and left to stand for 30 minutes. Thereafter, those were again shaken and centrifuged at 3000 rpm for 10 minutes; the substance PF1022 extracted from the individual strains in the supernatant was assayed by liquid chromatography. column, LiChrospher 100 RP-18 (e) (Kanto Chemical CO.) was used;

the column temperature was 40°C ; the mobile phase was 80 % acetonitrile at a flow rate of 1.0 ml/min; the substance PF1022 was detected on the basis of the absorbance at 210 nm. The retention time of the substance PF1022 under the conditions was 5 minutes to 6 minutes. The experiments were carried out in duplicate. The average values of the assay results of the substance PF1022 extracted from the parent strain and the gene-introduced strain with the pABP/PFsyn are shown in Table 1.

[0043]

[Table 1]

Substance PF1022 (µg/ml)

Parent strain

88

Gene-introduced strain

222

[0044]

The substance PF1022 productivity of the gene-introduced strain was about 2.5-fold that of the parent strain. It is apparently shown that the excess expression of the inventive cyclic depsipeptide synthetase elevates the productivity of the substance PF1022.

[0045]

[ADVANTAGEOUS EFFECTS OF THE INVENTION]

The introduction of the inventive cyclic depsipeptide synthetase gene in the fungus producing the substance PF1022 can improve the productivity of the substance PF1022.

[0046]

[SEQUENCE LISTING]

<110> Meiji Seika Kaisha, Ltd

<120> Cyclodepsipeptide synthetase gene

<130> PM1533

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 9633

<212> DNA

<213> Mycelia sterilia

<220>

<221> CDS

<222> (1).. (9633)

 $\langle 223 \rangle$ peptide synthetase for PF1022

<220>

<221> mat#peptide

<222> (13).. (9630)

<400> 1

atg tca aac atg gca cca ctc cct acg atg ggc gtt gag cag caa gcc 48

Met Ser Asn Met Ala Pro Leu Pro Thr Met Gly Val Glu Gln Gln Ala

-1 1 5 10

cta tca ctt tca tgc ccc tta ctc cct cat gac gat gag aaa cac tca 96 Leu Ser Leu Ser Cys Pro Leu Leu Pro His Asp Asp Glu Lys His Ser

15 20 25

gac aac ctt tac gag caa gca act cgg cac ttc ggc ttg agc cga gac 144
Asp Asn Leu Tyr Glu Gln Ala Thr Arg His Phe Gly Leu Ser Arg Asp

30 35 40

aag atc gaa aat gtc tta cca tgt act tcc ttt caa tgt gat gtc ata 192 Lys Ile Glu Asn Val Leu Pro Cys Thr Ser Phe Gln Cys Asp Val Ile

45 50 55 60

gat tgc gcc gtc gac gat cgg cgg cat gct atc ggt cac gtc gtc tat 240
Asp Cys Ala Val Asp Asp Arg Arg His Ala Ile Gly His Val Val Tyr

65 70 75

gat atc ccc aat aca gtg gac atc cag cgt tta gcc gca gcc tgg aaa 288
Asp Ile Pro Asn Thr Val Asp Ile Gln Arg Leu Ala Ala Ala Trp Lys

80 85 90

gag gtt gtg cgg cag aca cca atc ttg agg acc ggc atc ttt aca tca 336 Glu Val Val Arg Gln Thr Pro IIe Leu Arg Thr Gly IIe Phe Thr Ser

95 100 105

gaa acc ggc gac tot tit cag atc gtc tig aaa gaa ggc tgc cta ccg 384.

Glu Thr Gly Asp Ser Phe Gin Ile Val Leu Lys Glu Gly Cys Leu Pro

125

115

130

tgg atg tac gcg aca tgt ctc ggc atg aag ggg gca gtg ata caa gat 432

Trp Met Tyr Ala Thr Cys Leu Gly Met Lys Gly Ala Val Ile Gln Asp

135

140

gaa gca gtc gcc gct atg act gga ccg cgt tgc aat cga tat gtc gtc 480 Glu Ala Val Ala Ala Met Thr Gly Pro Arg Cys Asn Arg Tyr Val Val

ctg gag gac ccg agt acg aag caa agg ctg ctc atc tgg aca ttc agc 528

Leu Glu Asp Pro Ser Thr Lys Gln Arg Leu Leu Ile Trp Thr Phe Ser

160 165 170

cat gct tta gtg gat tat aca gtc cag gaa cgc atc ctt cag cgg gtt 576

His Ala Leu Val Asp Tyr Thr Val Gln Glu Arg Ile Leu Gln Arg Val

175

180

185

ctc aca gta tac gac ggc cgg gac gtc gag tgc cct cgc atc aag gat 624 Leu Thr Val Tyr Asp Gly Arg Asp Val Glu Cys Pro Arg Ile Lys Asp

190 195 200

aca gaa cat gtc tct cgg ttt tgg caa caa cac ttt gaa ggc tta gat 672

Thr Glu His Val Ser Arg Phe Trp Gln Gln His Phe Glu Gly Leu Asp

205 210 215 220

gcc tcc gta ttt ccc ctt cta cca tct cac cta act gtg tgc aat ccc 720

Ala Ser Val Phe Pro Leu Leu Pro Ser His Leu Thr Val Cys Asn Pro

225

230

235

aat gcg cgc gca gaa cat cat atc tca tac acg gga cca gtc cag agg 768
Asn Ala Arg Ala Glu His His Ile Ser Tyr Thr Gly Pro Val Gln Arg

240 245 250

aag tgg tcc cat aca agt atc tgt cgg gct gca ctc gca gtt ctt cta 816

Lys Trp Ser His Thr Ser Ile Cys Arg Ala Ala Leu Ala Val Leu Leu

255 260 265

tct cgc ttt aca cac tct tcg gag gcc ctc ttc ggt gtt gtg aca gaa 864
Ser Arg Phe Thr His Ser Ser Glu Ala Leu Phe Gly Val Val Thr Glu

270 275 280

Caa tot cac aac too gag gac caa aga cgg toa att gat ggc coc gca 912 Gln Ser His Asn Ser Glu Asp Gln Arg Arg Ser Ile Asp Gly Pro Ala agg aca gta gtg cct atc cgc gtc ctt tgt gcc cca gat caa tat gtg 960

Arg Thr Val Val Pro Ile Arg Val Leu Cys Ala Pro Asp Gln Tyr Val

tcg gat gtc att ggg gca atc acc gca cac gaa cac gcc atg cgc ggg 1008

Ser Asp Val Ile Gly Ala Ile Thr Ala His Glu His Ala Met Arg Gly

ttt gag cac gct gga ctt cgc aat atc cgc cgt acc gga gac gac ggg 1056 Phe Glu His Ala Gly Leu Arg Asn Ile Arg Arg Thr Gly Asp Asp Gly

tct gct gct tgt gga ttc cag acc gtg cta ctg gtg act gac ggt gat 1104

Ser Ala Ala Cys Gly Phe Gln Thr Val Leu Leu Val Thr Asp Gly Asp

350 355 360

gct ccc aag acc cct ggg agt gta ctt cat cga agt gta gaa gaa tcg 1152 Ala Pro Lys Thr Pro Gly Ser Val Leu His Arg Ser Val Glu Glu Ser 365 370 375 380

gat aga ttc atg ccc tgc gct aat cgt gcc ctt ctg ctc gac tgc cag 1200
Asp Arg Phe Met Pro Cys Ala Asn Arg Ala Leu Leu Leu Asp Cys Gln
385 390 395

atg gct ggc aac tcg gca tcc cta gtc gca cga tat gat cat aat gtg 1248 Met Ala Gly Asn Ser Ala Ser Leu Val Ala Arg Tyr Asp His Asn Val

400 405 410

atc gac cca cgc cag atg tct cgc ttc ctg cga cag cta gga tac ctg 1296

Ile Asp Pro Arg Gln Met Ser Arg Phe Leu Arg Gln Leu Gly Tyr Leu

415 420 425

atc caa caa ttt cat cat cac gtc gat ctg cct ctg gtc aaa gaa ctg 1344

Ile Gln Gln Phe His His Val Asp Leu Pro Leu Val Lys Glu Leu

430 435 440

gac gtc gtg acg gcg gag gat tgt gcg gaa atc gag aaa tgg aat tca 1392

Asp Val Val Thr Ala Glu Asp Cys Ala Glu Ile Glu Lys Trp Asn Ser

445 450 450 460

gaa cgc cta aca atg caa gac gcc tta atc cac gac acc ata tcc aag 1440

Glu Arg Leu Thr Met Gln Asp Ala Leu Ile His Asp Thr Ile Ser Lys

tgg gct gct ggc gat ccc aac aaa gct gca gtt ttc gct tgg gat ggg 1488

Trp Ala Ala Gly Asp Pro Asn Lys Ala Ala Val Phe Ala Trp Asp Gly

gaa tgg aca tac gcc gag cta gac aac ata tcc tcc cgt ctc gcc gtg 1536 Glu Trp Thr Tyr Ala Glu Leu Asp Asn Ile Ser Ser Arg Leu Ala Val

tat atc caa tcc ctg gac ttg aga cca gga caa gca ata ctc cca ctc 1584

Tyr Ile Gln Ser Leu Asp Leu Arg Pro Gly Gln Ala Ile Leu Pro Leu

- 32 -

tgc ttc gag aag tca aaa tgg gtc gtc gcc aca att ctc gcc gtc ctc 1632

Cys Phe Glu Lys Ser Lys Trp Val Val Ala Thr Ile Leu Ala Val Leu

525 530 540

aaa gtc ggt cgg gca ttc aca ctc atc gac ccg tgc gac ccc tcg gca 1680

Lys Val Gly Arg Ala Phe Thr Leu IIe Asp Pro Cys Asp Pro Ser Ala

545 550 555

agg atg gcc cag gtc tgt cag cag acc tcc gcc aca gtc gct ctc acc 1728

Arg Met Ala Gln Val Cys Gln Gln Thr Ser Ala Thr Val Ala Leu Thr

560 565 570

tcc aaa ctc cac aac acc tta cgt tcc gtc gtt tcc cgc tgc att 1776 . Ser Lys Leu His Asn Thr Thr Leu Arg Ser Val Val Ser Arg Cys Ile 575

580 585

gtg gtc gac gac gtc ctt cgg tcc tta ccc cac gcc gat ggc cgc 1824

Val Val Asp Asp Leu Leu Arg Ser Leu Pro His Ala Asp Gly Arg

590 595 600

tta aag gcc acc gtg aag cca cag gac ttg gcc tat gtt att ttc aca 1872

Leu Lys Ala Thr Val Lys Pro Gln Asp Leu Ala Tyr Val Ile Phe Thr

605 610 615 620

tct ggc agc aca gga gag ccg aaa ggc atc atg atc gaa cat cgg ggg 1920

Ser Gly Ser Thr Gly Glu Pro Lys Gly Ile Met Ile Glu His Arg Gly

625 630 635

ttc gtg tcg tgt gct atg aaa ttt ggc ccc gcg ctc gga atg gat gag 1968

Phe Val Ser Cys Ala Met Lys Phe Gly Pro Ala Leu Gly Met Asp Glu

cac acg cgc gct ctt caa ttc gcc tca tat gcg ttt ggc gct tgt ctg 2016 His Thr Arg Ala Leu Gln Phe Ala Ser Tyr Ala Phe Gly Ala Cys Leu

gta gaa gtt gtg aca gct ctg atg cac ggc ggc tgc gtc tgc atc cct 2064 Val Glu Val Val Thr Ala Leu Met His Gly Gly Cys Val Cys Ile Pro

tcc gat gac gat cgc ttg aac aat gta ccg gag ttc atc aaa agg gcc 2112 Ser Asp Asp Asp Arg Leu Asn Asn Val Pro Glu Phe Ile Lys Arg Ala

cag gtg aac tgg gtg ata ctc act ccg tcg tat atc ggg aca ttc cag 2160 Gln Val Asn Trp Val Ile Leu Thr Pro Ser Tyr Ile Gly Thr Phe Gln

705

710

715

ccg gaa gat gtc cct gga cta caa aca ctg gta ttg gtt gga gaa cct 2208

Pro Glu Asp Val Pro Gly Leu Gln Thr Leu Val Leu Val Gly Glu Pro

720

725

730

atc tca gcg tct att cgg gat acc tgg gcc tcc cag gtt cga ctc ctg 2256

Ile Ser Ala Ser Ile Arg Asp Thr Trp Ala Ser Gln Val Arg Leu Leu

735

740

745

aat gcc tac ggt cag agt gaa agc tca act atg tgc agc gtc acg gaa 2304 Asn Ala Tyr Gly Gln Ser Glu Ser Ser Thr Met Cys Ser Val Thr Glu 750

755

760

gtc agc ccg ctc tcc ctc gaa ccg aac aat atc ggt cgg gct gta ggc 2352

Val Ser Pro Leu Ser Leu Glu Pro Asn Asn Ile Gly Arg Ala Val Gly

765 770 780

gca cga tcc tgg atc att gat ccc gac gag cct gat cgt ctt gct cca 2400

Ala Arg Ser Trp Ile Ile Asp Pro Asp Glu Pro Asp Arg Leu Ala Pro

785 790 795

att ggc tgc att gga gag cta gtg atc gaa agt ccg ggc att gcg cgc 2448

Ile Gly Cys Ile Gly Glu Leu Val Ile Glu Ser Pro Gly Ile Ala Arg

. 800

805

gac tat atc atc gcg ccg ccg ccg gac aag tcc ccc ttt ctc cta gca

Asp Tyr Ile Ile Ala Pro Pro Pro Asp Lys Ser Pro Phe Leu Leu Ala

815

820

825

ccc ccg gcc tgg tat cca gcc ggg aaa tta tcc aac gcc ttt aaa ttt 2544

Pro Pro Ala Trp Tyr Pro Ala Gly Lys Leu Ser Asn Ala Phe Lys Phe

830

835

840.

tac aag act gga gat ctc gtg cgt tat gga cct gac ggc acc atc gte

2592

Tyr Lys Thr Gly Asp Leu Val Arg Tyr Gly Pro Asp Gly Thr Ile Val

845

850

855

860

tgc ctg gga cgc aaa gat tcg caa gtg aag atc cga ggg cag cgc gta

2640

Cys Leu Gly Arg Lys Asp Ser Gln Val Lys Ile Arg Gly Gln Arg Val

865

870

gag atc agc gca gtg gaa gcc agt cta cga cga caa cta cct agt gac 2688 Glu Ile Ser Ala Val Glu Ala Ser Leu Arg Arg Gln Leu Pro Ser Asp

880

885

890

atc atg ccc gtg gcc gaa gct atc aaa cgc tcg gat tcg tca ggc agc 2736 . Ile Met Pro Val Ala Glu Ala Ile Lys Arg Ser Asp Ser Ser Gly Ser

895

900

905

aca gtc ttg act gcc ttc ttg ata ggg tca tct aag agc gga gat ggt 2784

Thr Val Leu Thr Ala Phe Leu Ile Gly Ser Ser Lys Ser Gly Asp Gly

910

915

920

aat ggc cac gct tta tct gcg gca gac gcc gtt atc ttg gat cac ggt 2832

Asn	Gly	r His	Ala	Leu	Ser	Ala	Ala	Asp	Ala	Val	Ile	Leu	ı Asp	His	Gly	
925					930					935					940	
gct	acc	aac	gag	ata	aac	gcg	aag	ttg	cag	caa	atc	ctt	ccc	cag	cat	2880
Ala	Thr	Asn	Glu	Ile	Asn	Ala	Lys	Leu	Gln	Gln	Ile	Leu	Pro	Gln	His	
				945					950					955		
	-								•					500		
tcc	gtt	cca	tcc	tat	tat	atc	cac	atg	gaa	aat	ctt	cct	cga	act	gcc	2928
Ser	Val	Pro	Ser	Tyr	Туг	Ile	His	Me t	Glu	Asn	Leu	Pro	Arg	Thr	Ala	
			960			,		965					970			
						•										
																
acc	ggc	aaa	gcg	gac	agg	aaa	atg	ctt	cga	tct	att	gct	agc	aag	cta	2976
Thr	Gly	Lys	Ala	Asp	Arg	Lys	Me t	Leu	Arg	Ser	Ile	Ala	Ser	Lys	Leu	
		975					980 -					985				

ttg ggt gaa ttg tct cag aac gtg aca tct caa ccg att gag aag cac Leu Gly Glu Leu Ser Gln Asn Val Thr Ser Gln Pro Ile Glu Lys His

gat gcc cca gca act ggt ata gag gtc aag ctg aag gag ctt tgg ttt Asp Ala Pro Ala Thr Gly Ile Glu Val Lys Leu Lys Glu Leu Trp Phe

ctg agc ttg aat ctt aat ccc aac tct caa gat gtc gga gcg agt ttc Leu Ser Leu Asn Leu Asn Pro Asn Ser Gln Asp Val Gly Ala Ser Phe

ttt gac tta ggc gga aat tcc att atc gcc atc aaa atg gta aac atg Phe Asp Leu Gly Gly Asn Ser Ile Ile Ala Ile Lys Met Val Asn Met

1040

1045

1050

gcg agg tca gct ggg ata gca ctg aag gta tcc gac ata ttc cag aat 3216 Ala Arg Ser Ala Gly Ile Ala Leu Lys Val Ser Asp Ile Phe Gln Asn

1055

1060

1065

ccc acg ctc gcc ggc ctt gtg gat gtc atc ggg cga gac ccg gct ccg 3264
Pro Thr Leu Ala Gly Leu Val Asp Val Ile Gly Arg Asp Pro Ala Pro

1070

1075

1080

tac aac ctc atc cca aca aca gca tac agc gga cct gtt gag cag tcg 3312

Tyr Asn Leu Ile Pro Thr Thr Ala Tyr Ser Gly Pro Val Glu Gln Ser

1085 1090 1095 1100

ttc gcc cag ggc cgt cta tgg ttc ttg gac cag atc gaa ctc gat gcg 3360

Phe Ala Gln Gly Arg Leu Trp Phe Leu Asp Gln Ile Glu Leu Asp Ala

ttg tgg tac ctt cta cca tac gcc gtt cgc atg cgc ggg cca ttg cat 3408 Leu Trp Tyr Leu Leu Pro Tyr Ala Val Arg Met Arg Gly Pro Leu His

att gat gcg ctc act att gcg ttg cta gct ata cag caa cga cat gaa 3456 Ile Asp Ala Leu Thr Ile Ala Leu Leu Ala Ile Gln Gln Arg His Glu

acc ttg cgg aca acc ttt gag gag cag gac ggc gta ggc gtt cag gtt 3504

Thr Leu Arg Thr Thr Phe Glu Glu Gln Asp Gly Val Gly Val Gln Val

gtc cat gcg agc ccc atc tcc gac ttg agg ata atc gac gta tca ggc 3552

Val His Ala Ser Pro Ile Ser Asp Leu Arg Ile Ile Asp Val Ser Gly

1165 1170 1175 1180

gac cga aac agt gac tac ctc cag ttg cta cac caa gag cag acg act 3600
Asp Arg Asn Ser Asp Tyr Leu Gln Leu Leu His Gln Glu Gln Thr Thr

cca ttc att cta gca tgt cag gca gga tgg agg gta tca ctg att aga 3648

Pro Phe Ile Leu Ala Cys Gln Ala Gly Trp Arg Val Ser Leu Ile Arg

1200 1205 1210

cta gga gaa gat gat cac atc ctc tct atc gta atg cat cac atc atc 3696

Leu Gly Glu Asp Asp His Ile Leu Ser Ile Val Met His His Ile Ile

1215

1230

1220

1235

1225

1240

tcc gac ggc tgg tct atc gac att cta cgc cgg gaa cta agc aat ttc 3744 Ser Asp Gly Trp Ser Ile Asp Ile Leu Arg Arg Glu Leu Ser Asn Phe

tat toa goo got oto ogg ggo tot gat oot ota tog gtg gtg ago coa 3792

Tyr Ser Ala Ala Leu Arg Gly Ser Asp Pro Leu Ser Val Val Ser Pro

1245 1250 1255 1260

ctc cca ctc cac tac cgc gac ttt tcc gtt tgg caa aag cag gtc gaa 3840 Leu Pro Leu His Tyr Arg Asp Phe Ser Val Trp Gln Lys Gln Val Glu

1265

1270

cag gag acc gaa cat gag cgg caa ctc gaa tac tgg gtc aag cag ctc 3888 Gln Glu Thr Glu His Glu Arg Gln Leu Glu Tyr Trp Val Lys Gln Leu

1280 1285 1290

gca gac agc tcg gcc gcc gaa ttc cta acc gac ttc ccc cga ccc aac 3936
Ala Asp Ser Ser Ala Ala Glu Phe Leu Thr Asp Phe Pro Arg Pro Asn
1295 1300 1305

ata ctg tcc ggt gaa gca ggt tcc gtg cca gtg acg atc gaa ggc gaa 3984

Ile Leu Ser Gly Glu Ala Gly Ser Val Pro Val Thr Ile Glu Gly Glu

1310 1315 1320

ctg tat gaa agg ctc caa gaa ttc tgt aaa gta gag caa atg acg cct 4032
Leu Tyr Glu Arg Leu Gln Glu Phe Cys Lys Val Glu Gln Met Thr Pro

1325 1330 1335 1340

ttc gcc gtg ttg tta ggg gcc ttc cgc gcg acc cat tat cgt ctc acc 4080

Phe Ala Val Leu Leu Gly Ala Phe Arg Ala Thr His Tyr Arg Leu Thr

1345 1350 1355

ggc gcc gaa gac tcg atc atc ggc acg ccc atc gcg aac cgc aac cgc 4128 Gly Ala Glu Asp Ser Ile Ile Gly Thr Pro Ile Ala Asn Arg Asn Arg

1360 1365 1370

cag gag ctt gaa aac atg atc ggc ttc ttc gtc aac acc caa tgc atg 4176 Gln Glu Leu Glu Asn Met Ile Gly Phe Phe Val Asn Thr Gln Cys Met

1375 1380 1385

cga atc acg gtc gac ggc gac act ttt gaa agc ctg gtg cga caa 4224

Arg Ile Thr Val Asp Gly Asp Asp Thr Phe Glu Ser Leu Val Arg Gln

1390 1395 1400

gtt cgg acc acg gcg acg gca ttc gag cac caa gac gtc ccc ttt 4272

Val Arg Thr Thr Ala Thr Ala Ala Phe Glu His Gln Asp Val Pro Phe

1405 1410 1415 1420

gag cgc gtc gtg acg gca ctc ctt cca cgc tcg aga gac cta tcc cga 4320 Glu Arg Val Val Thr Ala Leu Leu Pro Arg Ser Arg Asp Leu Ser Arg

1425 1430 1435

aac cca cta gca cag ctc acc ttc gct ctt cat tct caa cag gac ctc 4368

Asn Pro Leu Ala Gln Leu Thr Phe Ala Leu His Ser Gln Gln Asp Leu

1440 1445 1450

ggc aag ttc gag ctg gag ggt ctc gta gcg gaa ccc gtc tcg aac aag 4416 Gly Lys Phe Glu Leu Glu Gly Leu Val Ala Glu Pro Val Ser Asn Lys 1455 1460 1465

gta tac acc agg ttc gac gtg gag ttt cac ctg ttc caa gaa gcc gga 4464

Val Tyr Thr Arg Phe Asp Val Glu Phe His Leu Phe Gln Glu Ala Gly

1470 1475 1480

aga cta agc ggt aac gtg gca ttt gcg gca gat cta ttc aag cct gag 4512

Arg Leu Ser Gly Asn Val Ala Phe Ala Ala Asp Leu Phe Lys Pro Glu

1485 1490 1495 1500

acc att agc aat gta gtc gcc ata ttt ttc caa atc ctg cga caa ggc 4560 Thr Ile Ser Asn Val Val Ala Ile Phe Phe Gln Ile Leu Arg Gln Gly att cgc cag cct cgg act cca atc gct gtt ctc ccg ctt acc gat ggg 4608

Ile Arg Gln Pro Arg Thr Pro Ile Ala Val Leu Pro Leu Thr Asp Gly

tta gcg gac ctt cgt gcc atg ggc ttg ctt gag atc gag aag gca gaa 4656 Leu Ala Asp Leu Arg Ala Met Gly Leu Leu Glu Ile Glu Lys Ala Glu

tac ccg cgg gag tcg agc gtc gtc gac gtc ttc cgc aag cag gtg gcc 4704

Tyr Pro Arg Glu Ser Ser Val Val Asp Val Phe Arg Lys Gln Val Ala

gct cac ccg cac gct ttt gcc gtt gtc gat tcg gca tcg cgc ctc aca 4752

Ala His Pro His Ala Phe Ala Val Val Asp Ser Ala Ser Arg Leu Thr 1565 1570 1575 1580

tat gct gat ctc gat cgt caa tcc gat caa ctc gcg acc tgg ctc ggt 4800

Tyr Ala Asp Leu Asp Arg Gln Ser Asp Gln Leu Ala Thr Trp Leu Gly

1585 1590 1595

cgg cgc aat atg acg gct gag acg ctg gtc ggg gtg tta gca ccg cgg 4848

Arg Arg Asn Met Thr Ala Glu Thr Leu Val Gly Val Leu Ala Pro Arg

tca tgt caa aca gtt gtt gcc att tta ggt atc ctg aaa gcg aat ctc 4896 Ser Cys Gln Thr Val Val Ala Ile Leu Gly Ile Leu Lys Ala Asn Leu

1615 1620 1625

Ala Tyr Leu Pro Leu Asp Val Asn Cys Pro Thr Ala Arg Leu Gln Thr

1630 1635 1640

atc cta tct aca ttg aat cgg cac aag ttg gtc cta ctc ggc tct aac 4992

Ile Leu Ser Thr Leu Asn Arg His Lys Leu Val Leu Leu Gly Ser Asn

1645 1650 1655 1660

gca act act ccg gat gtc cag ata cct gat gta gag ctg gta cga atc 5040

Ala Thr Thr Pro Asp Val Gln Ile Pro Asp Val Glu Leu Val Arg Ile

1665 1670 1675

agc gat atc tta gat cgc ccc atc aat ggc cag gca aag cta aat ggt 5088 Ser Asp Ile Leu Asp Arg Pro Ile Asn Gly Gln Ala Lys Leu Asn Gly 1680

1685

1690

cat aca aaa tog aat ggo tac toa aag coa aac ggo tat acg cat ctg 5136 His Thr Lys Ser Asn Gly Tyr Ser Lys Pro Asn Gly Tyr Thr His Leu

1695

1700

1705

aaa ggc tat tca aac cta aac ggt tat tca aaa caa aat ggt tat gca 5184 Lys Gly Tyr Ser Asn Leu Asn Gly Tyr Ser Lys Gln Asn Gly Tyr Ala

1710

1715

1720

Caa ctc aac ggc cat aga gag cgt aac aat tat tta gat cta aat ggg 5232

Gln Leu Asn Gly His Arg Glu Arg Asn Asn Tyr Leu Asp Leu Asn Gly

1725 1730 1735 1740

cac tca ctg cta aat ggg aat tca gac atc acc aca tca ggg ccc tca 5280 His Ser Leu Leu Asn Gly Asn Ser Asp Ile Thr Thr Ser Gly Pro Ser

1745 1750 1755

gca aca agc ctt gcc tac gtg atc ttc aca tcc ggc tca acc gga aag 5328

Ala Thr Ser Leu Ala Tyr Val Ile Phe Thr Ser Gly Ser Thr Gly Lys

1760 1765 . 1770

CCC aaa gga gtc atg gtc gaa cac cgc agc atc atc cga ctt gca aag 5376

Pro Lys Gly Val Met Val Glu His Arg Ser Ile Ile Arg Leu Ala Lys

1775 1780 1785

aag aac aga atc ata tcc agg ttc cca tct gta gcc aag gta gct cac 5424

Lys Asn Arg Ile Ile Ser Arg Phe Pro Ser Val Ala Lys Val Ala His

1790 1795 1800

ctc tca aac atc gcc ttt gac gcc gcc act tgg gaa atg ttc gca gcc 5472

Leu Ser Asn Ile Ala Phe Asp Ala Ala Thr Trp Glu Met Phe Ala Ala

1805 1810 1815 1820

ctt cta aac ggc gga acg ctg gtc tgt atc gac tat atg acc acc ctg 5520 Leu Leu Asn Gly Gly Thr Leu Val Cys Ile Asp Tyr Met Thr Thr Leu

1825 1830 1835

gac agc aaa acg ctc gag gcc gcg ttt gca cga gaa caa atc aac gcc 5568
Asp Ser Lys Thr Leu Glu Ala Ala Phe Ala Arg Glu Gln Ile Asn Ala

1845

1840

gcg tta ctc acg ccc gct ttg ttg aag cag tgc cta gcc aac att ccc 5616

Ala Leu Leu Thr Pro Ala Leu Leu Lys Gln Cys Leu Ala Asn Ile Pro

act acc cta ggc agg ctg agt gca ctc gtt att gga ggt gat agg ctt 5664
Thr Thr Leu Gly Arg Leu Ser Ala Leu Val Ile Gly Gly Asp Arg Leu

gac ggc caa gac gcg atc gca gca cat gcg ctt gtc ggt gct ggc gtg 5712

Asp Gly Gln Asp Ala Ile Ala Ala His Ala Leu Val Gly Ala Gly Val

1885 1890 1895 1900

tat aat gcg tat ggc ccg acc gaa aac gga gtg atc agt acg att tat 5760

Tyr Asn Ala Tyr Gly Pro Thr Glu Asn Gly Val Ile Ser Thr Ile Tyr

aat atc act aaa aac gac tcg ttc atc aac gga gtc ccc atc ggc tgt 5808

Asn Ile Thr Lys Asn Asp Ser Phe Ile Asn Gly Val Pro Ile Gly Cys

1920

1925

1930

gca atc agc aat tcc ggc gcc tac atc aca gac cca gac cag cag ctc 5856

Ala Ile Ser Asn Ser Gly Ala Tyr Ile Thr Asp Pro Asp Gln Gln Leu

1935

1940

1945

gta cct cct ggc gtc atg ggt gaa ctc gtc gtt acc ggt gac ggg ctc 5904

Val Pro Pro Gly Val Met Gly Glu Leu Val Val Thr Gly Asp Gly Leu

1950 1955 1960

gcg cgg ggg tat aca gac cca gca cta gac gcg ggc cgc ttc gtc cag

Ala Arg Gly Tyr Thr Asp Pro Ala Leu Asp Ala Gly Arg Phe Val Gln

atc atg atc aat gac aag gcc gtg agg gcg tac cga acg ggt gac cgg 6000

Ile Met Ile Asn Asp Lys Ala Val Arg Ala Tyr Arg Thr Gly Asp Arg

gca cga tat cgc gta gga gac ggt cag atc gag ttc ttc gga cgc atg 6048

Ala Arg Tyr Arg Val Gly Asp Gly Gln Ile Glu Phe Phe Gly Arg Met

gat cag caa gtc aag atc cga ggt cac cgc att gaa cca gcc gaa gtg 6096 Asp Gln Gln Val Lys Ile Arg Gly His Arg Ile Glu Pro Ala Glu Val

gag cgt gct att ctc gac caa gac tcg gcc cgc gac gcc gtc gtt gtc 6144

Glu Arg Ala Ile Leu Asp Gln Asp Ser Ala Arg Asp Ala Val Val

2035

2050

2030

2045

atc cgg cac caa gaa ggt gaa gaa ccg gag atg gtt ggt ttc gtc gcg 6192

Ile Arg His Gln Glu Gly Glu Pro Glu Met Val Gly Phe Val Ala

2055

2060

2040

acc cac ggc gat cac tct gcc gaa caa gag gaa gca gac gac cag gtt 6240

Thr His Gly Asp His Ser Ala Glu Gln Glu Glu Ala Asp Asp Gln Val

gaa ggt tgg aaa gac ttc ttc gag agc aat aca tat gcc gac atg gat 6288 Glu Gly Trp Lys Asp Phe Phe Glu Ser Asn Thr Tyr Ala Asp Met Asp

2080 2085 2090

acc atc ggc cag tct gct ata ggc aac gac ttt acg ggc tgg acg tcc 6336

Thr Ile Gly Gln Ser Ala Ile Gly Asn Asp Phe Thr Gly Trp Thr Ser

2095

2100

2105

atg tac gac ggg agc gag atc aac aag gcc gag atg cag gag tgg ctc 6384

Met Tyr Asp Gly Ser Glu Ile Asn Lys Ala Glu Met Gln Glu Trp Leu

2110 2115 2120

gac gac acc atg cgc aca ctc ctc gat ggc caa gcg ccg ggt cac gta 6432

Asp Asp Thr Met Arg Thr Leu Leu Asp Gly Gln Ala Pro Gly His Val

2125 2130 2135 2140

ctc gaa ata ggc aca ggc agt ggc atg gta ttg ttt aac tta ggg gcc 6480 Leu Glu Ile Gly Thr Gly Ser Gly Met Val Leu Phe Asn Leu Gly Ala ggg cta caa agc tac gta ggt ctt gaa cca tct aga tct gca gcc acg 6528 Gly Leu Gln Ser Tyr Val Gly Leu Glu Pro Ser Arg Ser Ala Ala Thr

ttt gtt acc aaa gcg atc aat tcc acc cca gct ctt gca gga aag gcc 6576 Phe Val Thr Lys Ala Fle Asn Ser Thr Pro Ala Leu Ala Gly Lys Ala

gaa gtg cac gtc ggc aca gcg aca gac ata aac cga ctt cgt gga ctt 6624 Glu Val His Val Gly Thr Ala Thr Asp Ile Asn Arg Leu Arg Gly Leu

cgt ccc gat cta gtt gtg ctc aac tcg gta gtc cag tat ttc ccc acg 6672

Arg Pro Asp Leu Val Val Leu Asn Ser Val Val Gln Tyr Phe Pro Thr

2205 2210 2215 2220

ccc gag tac cta cta gag gtc gtg gag agt ctc gtc cgg att ccg ggc 6720

Pro Glu Tyr Leu Leu Glu Val Val Glu Ser Leu Val Arg Ile Pro Gly

2225 2230 2235

gtc aag cgc gtg gtc ttc ggc gac ata cga tct cac gcc acg aac aga 6768

Val Lys Arg Val Val Phe Gly Asp IIe Arg Ser His Ala Thr Asn Arg

2240 2245 2250

cat tit cit gct gcc agg gcg cig cat tcg cig ggc tcc aag gcg acc 6816 His Phe Leu Ala Ala Arg Ala Leu His Ser Leu Gly Ser Lys Ala Thr

2255. 2260 2265

aaa gat gct ata cgt caa aag atg acg gag atg gaa gag cgc gag gaa 6864

Lys Asp Ala Ile Arg Gln Lys Met Thr Glu Met Glu Glu Arg Glu Glu

2270 2275 2280

gag ctg ctc gtc gac ccg gcc ttc ttc acg gcg ctg ctg cag ggc cag 6912

Glu Leu Leu Val Asp Pro Ala Phe Phe Thr Ala Leu Leu Gln Gly Gln

2285 2290 2295 2300

ctt gcc gat cga atc aag cac gtc gag atc ctc ccg aag aac atg cgc 6960

Leu Ala Asp Arg Ile Lys His Val Glu Ile Leu Pro Lys Asn Met Arg

2305 2310 2315

gcc acg aac gag ctg agc gcg tac cgg tat aca gcc gtc att cac gta 7008

Ala Thr Asn Glu Leu Ser Ala Tyr Arg Tyr Thr Ala Val Ile His Val

cgc ggc cca gag gaa cag tcg cgg ccc gtg tat ccg atc caa gtg aac

Arg Gly Pro Glu Glu Gln Ser Arg Pro Val Tyr Pro Ile Gln Val Asn

gac tgg atc gac ttt cag gcc tca cgc att gac cgc cgc gcc ctt ctc 7104
Asp Trp Ile Asp Phe Gln Ala Ser Arg Ile Asp Arg Ala Leu Leu

cga ctc cta cag cgc tcg gca gac gcc gcg acc gtc gcc gtc agc aac 7152

Arg Leu Leu Gln Arg Ser Ala Asp Ala Ala Thr Val Ala Val Ser Asn

atc ccc tac agc aag acg att gta gaa cgc cat gtc gtc gag tcc ctt 7200

Ile Pro Tyr Ser Lys Thr Ile Val Glu Arg His Val Val Glu Ser Leu

2385

2390

2395

gac aat aac aac agg gag aat acg cat aga gca cca gac ggc gcg gct 7248
Asp Asn Asn Asn Arg Glu Asn Thr His Arg Ala Pro Asp Gly Ala Ala

2400

2405

2410

tgg atc tcg gcc gtc cgc tcc aag gcc gag cgc tgc acg tcc ctc tcc 7296

Trp Ile Ser Ala Val Arg Ser Lys Ala Glu Arg Cys Thr Ser Leu Ser

2415

2420

2425

gtg acc gat ctt gtg cag ctc ggg gaa gaa gcc ggc ttt cgc gta gaa 7344 Val Thr Asp Leu Val Gln Leu Gly Glu Glu Ala Gly Phe Arg Val Glu gtc agc gca gcg cgg cag tgg tct caa agc ggc gcg ctc gat gcc gtc 7392

Val Ser Ala Ala Arg Gln Trp Ser Gln Ser Gly Ala Leu Asp Ala Val

2445 2450 2455 2460

ttt cac cgc tat aat ttg ccc act caa agc aat agt cgc gtt ctg att 7440

Phe His Arg Tyr Asn Leu Pro Thr Gln Ser Asn Ser Arg Val Leu Ile

2465 2470 2475

cag ttc cct acc gaa gat ggc cag acg cga aga tcc gcc act ctg aca 7488

Gln Phe Pro Thr Glu Asp Gly Gln Thr Arg Arg Ser Ala Thr Leu Thr

2480 2485 2490

aac cga cca cta cag cgt ctg cag agc cgt cgg ttc gca tca cag atc 7536

Asn Arg Pro Leu Gin Arg Leu Gin Ser Arg Arg Phe Ala Ser Gin Ile

2495

2500

2505

cgc gaa cag ctg aag gcc gtg ctc ccg tca tac atg atc ccc tcc cgc 7584

Arg Glu Gln Leu Lys Ala Val Leu Pro Ser Tyr Met Ile Pro Ser Arg

2510 2515 2520

atc gtg gtc ata gac cag atg cct ctc aat gcc aat ggc aag gtc gac 7632

Ile Val Val Ile Asp Gln Met Pro Leu Asn Ala Asn Gly Lys Val Asp

2525 2530 2535 2540

cgg aaa gaa ctt acc aga agg gcc caa atc gcg ccg aaa tct cag gcg 7680 Arg Lys Glu Leu Thr Arg Arg Ala Gln Ile Ala Pro Lys Ser Gln Ala

2545

2550

gct ccc gcc aaa ccc gtc aaa cag gtc gat ccg ttc gtc aac ctg gaa 7728

Ala Pro Ala Lys Pro Val Lys Gln Val Asp Pro Phe Val Asn Leu Glu

2560 2565 2570

gcc att tta tgt gag gag ttc gcg gag gtg ctg ggc atg gaa gtc ggc 7776

Ala Ile Leu Cys Glu Glu Phe Ala Glu Val Leu Gly Met Glu Val Gly

2575 2580 2585

gtg aac gac cac ttc ttc caa cta ggc gga cac tct ctc ttg gcc acg 7824
Val Asn Asp His Phe Phe Gln Leu Gly Gly His Ser Leu Leu Ala Thr

2590 2595 2600

aag ctc gtc gcg cgt ctc agt cgt cgg cta aac ggt cgt gtg tct gtg 7872 Lys Leu Val Ala Arg Leu Ser Arg Arg Leu Asn Gly Arg Val Ser Val

agg gat gtg ttc gac cag cct gtg att tcc gac ctc gca gtc acc ctc 7920 Arg Asp Val Phe Asp Gln Pro Val Ile Ser Asp Leu Ala Val Thr Leu

cgc cag gga ctg acc ttg gaa aac gcc att ccc gca acg ccg gac agc 7968

Arg Gln Gly Leu Thr Leu Glu Asn Ala Ile Pro Ala Thr Pro Asp Ser

ggg tat tgg gag cag aca atg tcc gca ccg aca acc ccg agc gac gac 8016 Gly Tyr Trp Glu Gln Thr Met Ser Ala Pro Thr Thr Pro Ser Asp Asp

atg gag gcc gtg cta tgc aag gag ttt gcg gat gtg ctt ggc gtc gaa 8064 Met Glu Ala Val Leu Cys Lys Glu Phe Ala Asp Val Leu Gly Val Glu

2670

2675

2680

gtc agc gcc acc gac agc ttc ttc gat ctc ggt ggg cat tcc ctc atg 8112

Val Ser Ala Thr Asp Ser Phe Phe Asp Leu Gly Gly His Ser Leu Met

2685 2690 2695 2700

gct acg aag ctc gct gcg cgt att agc cgt cgg cta gat gta ccg gtg 8160

Ala Thr Lys Leu Ala Ala Arg Ile Ser Arg Arg Leu Asp Val Pro Val

2705

2710

2715

tca atc aaa gac ata ttc gat cac tca gtt cct cta aac ctt gcg agg 8208 Ser Ile Lys Asp Ile Phe Asp His Ser Val Pro Leu Asn Leu Ala Arg

2720

2725

aag att cgg ctc act caa gca aaa ggc cac gaa gcg acc aat gga gta Lys Ile Arg Leu Thr Gln Ala Lys Gly His Glu Ala Thr Asn Gly Val

caa atc gcc aac gcc cca ttc caa ctc att tcc gta gaa gat cca Gln Ile Ala Asn Asp Ala Pro Phe Gln Leu Ile Ser Val Glu Asp Pro

gag ata ttc gtc caa cgt gaa atc gcc cct caa cta caa tgc tca ccc Glu Ile Phe Val Gln Arg Glu Ile Ala Pro Gln Leu Gln Cys Ser Pro

gag aca atc cta gac gtc tac ccc gcc acg caa atg caa agg gtc ttc

Glu Thr Ile Leu Asp Val Tyr Pro Ala Thr Gln Met Gln Arg Val Phe

ctc ctc aac cca gta aca gga aag ccg cgc tca cca acg cca ttt cac 8448

Leu Leu Asn Pro Val Thr Gly Lys Pro Arg Ser Pro Thr Pro Phe His

ata gac ttc ccg ccg gac gca gac tgc gcc agc ctg atg cgg gca tgt 8496

Ile Asp Phe Pro Pro Asp Ala Asp Cys Ala Ser Leu Met Arg Ala Cys

gca tct cta gcg aag cat ttc gat atc ttc agg acg gtg ttc ctc gaa 8544

Ala Ser Leu Ala Lys His Phe Asp Ile Phe Arg Thr Val Phe Leu Glu

gcc aga ggc gaa ctc tac caa gta gtt cta aaa cac gtc gac gtg ccc 8592

Ala Arg Gly Glu Leu Tyr Gln Val Val Leu Lys His Val Asp Val Pro
2845 2850 2855 2860

atc gag atg ctc cag acc gaa gaa aac atc aac agc gcg acc cgg tcg 8640

Ile Glu Met Leu Gln Thr Glu Glu Asn Ile Asn Ser Ala Thr Arg Ser

2865 2870 2875

ttc ctg gac gta gac gca gaa aaa ccc atc cgg cta ggc cag cca ctg 8688

Phe Leu Asp Val Asp Ala Glu Lys Pro IIe Arg Leu Gly Gln Pro Leu

2880 2885 2890

atc cgc atc gcg ata cta gag aag ccc ggg tcc acg ctg cgc gtc atc 8736. Ile Arg Ile Ala Ile Leu Glu Lys Pro Gly Ser Thr Leu Arg Val Ile

2925

2905

cta cga tta tcc cac gcc tta tac gac ggc ctg agc cta gag cac atc 8784

Leu Arg Leu Ser His Ala Leu Tyr Asp Gly Leu Ser Leu Glu His Ile

2910 2915 2920

2930

ctg cac tct ctg cac atc ctc ttt ttc ggc ggc agt ctt ccc ccg ccg 8832
Leu His Ser Leu His Ile Leu Phe Phe Gly Gly Ser Leu Pro Pro

2935

2940

CCC aag ttc gcc ggg tac atg caa cac gtc gcg agc agt cgc aga gaa 8880
Pro Lys Phe Ala Gly Tyr Met Gln His Val Ala Ser Ser Arg Arg Glu

2945 2950 2955

ggc tac gat ttc tgg cgt tcc gtt ctc cga gat tcg tct atg aca gtc 8928

Gly Tyr Asp Phe Trp Arg Ser Val Leu Arg Asp Ser Ser Met Thr Val

lle Lys Gly Asn Asn Asn Thr Thr Pro Pro Pro Pro Gln Gln Gln

tcc acc ccc tcc gga gcc cac cac gcc tcc aaa gta gtc act atc cca

Ser Thr Pro Ser Gly Ala His His Ala Ser Lys Val Val Thr Ile Pro

acc caa gcc aac aca gac agc cgg atc acg cgc gcc acg atc ttc act

Thr Gln Ala Asn Thr Asp Ser Arg Ile Thr Arg Ala Thr Ile Phe Thr

acc gct tgc gca cta atg ctc gcg aaa gaa gac aac tcc agc gac gtc 9120
Thr Ala Cys Ala Leu Met Leu Ala Lys Glu Asp Asn Ser Ser Asp Val

3025 3030 3035

gtc ttc ggg cgt acg gta tcg ggg cgt caa ggc ctg ccc cta gcc cac 9168

Val Phe Gly Arg Thr Val Ser Gly Arg Gln Gly Leu Pro Leu Ala His

3040 3045 3050

caa aac gtg atc gga cca tgt ctc aac caa gtg ccc gtg cgc gcg cgc 9216
Gln Asn Val Ile Gly Pro Cys Leu Asn Gln Val Pro Val Arg Ala Arg

3055 3060 3065

ggt tta aac cga gga acc act cac cga gaa ctt ctc cgc gag atg 9264 Gly Leu Asn Arg Gly Thr Thr His His Arg Glu Leu Leu Arg Glu Met

3075

3080

Gln Glu Gin Tyr Leu Asn Ser Leu Ala Phe Glu Thr Leu Gly Tyr Asp

3085
3090
3095
3100

gag atc aag gcg cac tgc aca gac tgg ccg gac gtg cca gcg acc gcg 9360 Glu Ile Lys Ala His Cys Thr Asp Trp Pro Asp Val Pro Ala Thr Ala

3105 3110 3115

age the ggg tgc tgc atc gtg tac cag aac the gat teg cac eeg gac 9408 Ser Phe Gly Cys Cys Ile Val Tyr Gln Asn Phe Asp Ser His Pro Asp

3120

3125

agc cga gtc gaa gag cag cgg ctg cag atc ggg gtc ttg tcg cgg aac 9456 Ser Arg Val Glu Glu Gln Arg Leu Gln Ile Gly Val Leu Ser Arg Asn

3135 3140 3145

tac gag gct att aat gag ggg ctc gtg cat gat ctt gtt att gct ggg 9504

Tyr Glu Ala Ile Asn Glu Gly Leu Val His Asp Leu Val Ile Ala Gly

3150 3155 3160.

gag tcg gag cct gat ggg gat gat ttg agg gtt act gtt gtg gcg aat 9552
Glu Ser Glu Pro Asp Gly Asp Asp Leu Arg Val Thr Val Val Ala Asn
3165 3170 3175 3180

cgg agg ttg tgc gat gag gaa agg ttg aag agg atg ctg gag gag ctg 9600 Arg Arg Leu Cys Asp Glu Glu Arg Leu Lys Arg Met Leu Glu Glu Leu

3185 3190 3195

tgt ggg aat att cgg gct ttg gcg ttg gtt tag

9633

Cys Gly Asn Ile Arg Ala Leu Ala Leu Val

3200

3205

<210> 2

<211> 3210

<212> PRT

<213> Mycelia sterilia

<400> 2

Met Ser Asn Met Ala Pro Leu Pro Thr Met Gly Val Glu Gln Gln Ala

١,

5 .

10

Leu Ser Leu Ser Cys Pro Leu Leu Pro His Asp Asp Glu Lys His Ser

20 25 30

Asp Asn Leu Tyr Glu Gln Ala Thr Arg His Phe Gly Leu Ser Arg Asp

35 40 45

Lys Ile Glu Asn Val Leu Pro Cys Thr Ser Phe Gln Cys Asp Val Ile

50 . 55 60

Asp Cys Ala Val Asp Asp Arg Arg His Ala Ile Gly His Val Val Tyr

65 70 75 80

Asp Ile Pro Asn Thr Val Asp Ile Gln Arg Leu Ala Ala Ala Trp Lys

85 90 95

Glu Val Val Arg Gln Thr Pro Ile Leu Arg Thr Gly Ile Phe Thr Ser

Glu Thr Gly Asp Ser Phe Gln Ile Val Leu Lys Glu Gly Cys Leu Pro

115 120 . 125

Trp Met Tyr Ala Thr Cys Leu Gly Met Lys Gly Ala Val Ile Gln Asp

130 135 140

Glu Ala Val Ala Ala Met Thr Gly Pro Arg Cys Asn Arg Tyr Val Val

145 150 155 160

Leu Glu Asp Pro Ser Thr Lys Gln Arg Leu Leu Ile Trp Thr Phe Ser

His Ala Leu Val Asp Tyr Thr Val Gln Glu Arg Ile Leu Gln Arg Val

Leu Thr Val Tyr Asp Gly Arg Asp Val Glu Cys Pro Arg Ile Lys Asp

Thr Glu His Val Ser Arg Phe Trp Gln Gln His Phe Glu Gly Leu Asp

Ala Ser Val Phe Pro Leu Leu Pro Ser His Leu Thr Val Cys Asn Pro

Asn Ala Arg Ala Glu His His Ile Ser Tyr Thr Gly Pro Val Gln Arg

Lys Trp Ser His Thr Ser Ile Cys Arg Ala Ala Leu Ala Val Leu Leu

Ser Arg Phe Thr His Ser Ser Glu Ala Leu Phe Gly Val Val Thr Glu

Gln Ser His Asn Ser Glu Asp Gln Arg Arg Ser Ile Asp Gly Pro Ala

Arg Thr Val Val Pro Ile Arg Val Leu Cys Ala Pro Asp Gln Tyr Val

Ser Asp Val Ile Gly Ala Ile Thr Ala His Glu His Ala Met Arg Gly

325 330 335

Phe Glu His Ala Gly Leu Arg Asn Ile Arg Arg Thr Gly Asp Asp Gly

340 345 350

Ser Ala Ala Cys Gly Phe Gln Thr Val Leu Leu Val Thr Asp Gly Asp

355 360 365

Ala Pro Lys Thr Pro Gly Ser Val Leu His Arg Ser Val Glu Glu Ser

370 375 380

Asp Arg Phe Met Pro Cys Ala Asn Arg Ala Leu Leu Leu Asp Cys Gln
385
390
395
400

Met Ala Gly Asn Ser Ala Ser Leu Val Ala Arg Tyr Asp His Asn Val

405 410 415

Ile Asp Pro Arg Gln Met Ser Arg Phe Leu Arg Gln Leu Gly Tyr Leu

420 425 430

Ile Gln Gln Phe His His His Val Asp Leu Pro Leu Val Lys Glu Leu
435 440 445

Asp Val Val Thr Ala Glu Asp Cys Ala Glu Ile Glu Lys Trp Asn Ser
450 455 460

Glu Arg Leu Thr Met Gln Asp Ala Leu Ile His Asp Thr Ile Ser Lys
465 470 475 480

Trp	Ala	Ala	Gly	Asp	Pro	Asn	Lys	Ala	Ala	Val	Phe	Ala	Trp	Asp	Gly
				485					490			-		495	
Glu	Trp	Thr	Tyr	Ala	Glu	Leu	Asp	Asn	Ile	Ser	Ser	Arg	Leu	Ala	Val
			500					505					510		
												•			
Tyr	Ile	Gln _.	Ser	Leu	Asp	Leu	Arg	Pro	Gly	Gln	Ala	Ile	Leu	Pro	Leu
		515					520					525			
Cys	Phe	Glu	Lys	Ser	Lys	Trp	Val	Val	Ala	Thr	Ile	Leu	Ala	Val	Leu
	530					535					540				
Lys	Val	Gly	Arg	Ala	Phe	Thr	Leu	lle	Asp	Pro	Cys	Asp	Pro	Ser	Ala

Arg Met Ala Gln Val Cys Gln Gln Thr Ser Ala Thr Val Ala Leu Thr

Ser Lys Leu His Asn Thr Thr Leu Arg Ser Val Val Ser Arg Cys Ile

Val Val Asp Asp Leu Leu Arg Ser Leu Pro His Ala Asp Gly Arg

Leu Lys Ala Thr Val Lys Pro Gln Asp Leu Ala Tyr Val Ile Phe Thr

Ser Gly Ser Thr Gly Glu Pro Lys Gly Ile Met Ile Glu His Arg Gly

Phe Val Ser Cys Ala Met Lys Phe Gly Pro Ala Leu Gly Met Asp Glu

His Thr Arg Ala Leu Gln Phe Ala Ser Tyr Ala Phe Gly Ala Cys Leu

Val Glu Val Val Thr Ala Leu Met His Gly Gly Cys Val Cys Ile Pro

Ser Asp Asp Asp Arg Leu Asn Asn Val Pro Glu Phe Ile Lys Arg Ala

Gln Val Asn Trp Val IIe Leu Thr Pro Ser Tyr IIe Gly Thr Phe Gln

Pro Glu Asp Val Pro Gly Leu Gln Thr Leu Val Leu Val Gly Glu Pro

Ile Ser Ala Ser Ile Arg Asp Thr Trp Ala Ser Gln Val Arg Leu Leu

Asn Ala Tyr Gly Gln Ser Glu Ser Ser Thr Met Cys Ser Val Thr Glu

Val Ser Pro Leu Ser Leu Glu Pro Asn Asn Ile Gly Arg Ala Val Gly

Ala	Arg	Ser	Trp	Ile	He	Asp	Pro	Asp	Glu	Pro	Asp	Arg	Leu	Ala	Pro
785					790					795	i				800
												-			
He	Gly	Cys	Ile	Gly	Glu	Leu	Val	Ile	Glu	Ser	Pro	Gly	Ile	Ala	Arg
			·	805					810					815	
Asp	Tyr	Ile	Ile	Ala	Pro	Pro	Pro	Asp	Lys	Ser	Pro	Phe	Leu	Leu	Ala
			820					825				:···	830		
					-				•						
Pro	Pro	Ala	Trp	Tyr	Pro	Ala	Gly	Lys	Leu	Ser	Asn	Ala	Phe	Lys	Phe
		835					840					845			
Гуг	Lys	Thr	Gly	Asp	Leu	Val	Arg	Tyr	Gly	Pro	Asp	Gly	Thr	Ile	Val
								-	-		-	•			- -
	850			_		855					860				

cys Leu (ily alg Lys	Asp Ser	GIN Va	l Lys i	le Arg	Gly G	ln Arg	g Val
865		870		8	75			880
Glu Ile S	er Ala Val	Glu Ala	Ser Leu	Arg A	rg Gln	Leu Pi	o Ser	Asp
	885			890			895	
Ile Met Pr	o Val Ala (Glu Ala 1	lle Lys	Arg Se	r Asp	Ser Se	r Gly	Ser
	900		905			91	0	,
Thr Val Let	u Thr Ala P	he Leu I	le Gly	Ser Se	r Lys	Ser Gly	/ Asp	Gly
915	5	9	20		9	925		
·	,							

Asn Gly His Ala Leu Ser Ala Ala Asp Ala Val Ile Leu Asp His Gly

935

930

Ala	Thr	Asn	Glu	Ile	Asn	Ala	Lys	Leu	Gln	Gln	Ile	Leu	Pro	Gln	His
945					950					955					960

Ser Val Pro Ser Tyr Tyr Ile His Met Glu Asn Leu Pro Arg Thr Ala
965 970 975

Thr Gly Lys Ala Asp Arg Lys Met Leu Arg Ser Ile Ala Ser Lys Leu
980 985 990

Leu Gly Glu Leu Ser Gln Asn Val Thr Ser Gln Pro Ile Glu Lys His
995 1000 1005

Asp Ala Pro Ala Thr Gly Ile Glu Val Lys Leu Lys Glu Leu Trp Phe

Leu Ser Leu Asn Leu Asn Pro Asn Ser Gln Asp Val Gly Ala Ser Phe

Phe Asp Leu Gly Gly Asn Ser Ile Ile Ala Ile Lys Met Val Asn Met

Ala Arg Ser Ala Gly Ile Ala Leu Lys Val Ser Asp Ile Phe Gln Asn

Pro Thr Leu Ala Gly Leu Val Asp Val Ile Gly Arg Asp Pro Ala Pro

Tyr Asn Leu Ile Pro Thr Thr Ala Tyr Ser Gly Pro Val Glu Gln Ser

Phe Ala Gln Gly Arg Leu Trp Phe Leu Asp Gln Ile Glu Leu Asp Ala

Leu Trp Tyr Leu Leu Pro Tyr Ala Val Arg Met Arg Gly Pro Leu His

Ile Asp Ala Leu Thr Ile Ala Leu Leu Ala Ile Gln Gln Arg His Glu

Thr Leu Arg Thr Thr Phe Glu Glu Gln Asp Gly Val Gly Val Gln Val

Val	His	s Ala	Ser	Pro	Ile	Ser	Asp	Leu	Ārg	; Ile	Ile	Asp	Val	Ser	Gly
	1170)				1175					1180				
Asp	Arg	Asn	Ser	Asp	Tyr	Leu	Gln	Leu	Leu	His	Gln	Glu	Gln	Thr	Thr
185			٠		1190					1195					1200
			•												
Pro	Phe	Ile	Leu	Ala	Cys	Gln	Ala	Gly	Trp	Arg	Val	Ser	Leu	Ile	Arg
				1205					1210					1215	
							~								
Leu	Gly	Glu	Asp	Asp	His	Ile	Leu	Ser	Ile	Val	Met	His	His	Ile	Ile
-	•	I	220			٠	1	225				1	.230		
		•													
Ser	Asp	Gly	Trp	Ser	Ile	Asp	Ile	Leu	Arg	Arg	Glu	Leu	Ser	Asn	Phe

Tyr	Ser	Ala	Ala	Leu	Arg	Gly	Ser	Asp	Pro	Leu	Ser	Val	Val	Ser	Pro
	1250					1255					1260				

Leu Pro Leu His Tyr Arg Asp Phe Ser Val Trp Gln Lys Gln Val Glu 265 1270 1275 1280

Gln Glu Thr Glu His Glu Arg Gln Leu Glu Tyr Trp Val Lys Gln Leu
1285 1290 1295

Ala Asp Ser Ser Ala Ala Glu Phe Leu Thr Asp Phe Pro Arg Pro Asn 1300 1305 1310

Ile Leu Ser Gly Glu Ala Gly Ser Val Pro Val Thr Ile Glu Gly Glu
1315 1320 1325

Leu Tyr Glu Arg Leu Gln Glu Phe Cys Lys Val Glu Gln Met Thr Pro 1330 1335 1340

Phe Ala Val Leu Leu Gly Ala Phe Arg Ala Thr His Tyr Arg Leu Thr

345 1350 1355 1360

Gly Ala Glu Asp Ser Ile Ile Gly Thr Pro Ile Ala Asn Arg Asn Arg
1365 1370 1375

Gln Glu Leu Glu Asn Met Ile Gly Phe Phe Val Asn Thr Gln Cys Met 1380 1385 1390

Arg Ile Thr Val Asp Gly Asp Asp Thr Phe Glu Ser Leu Val Arg Gln

1395 1400 1405

Val	Arg	Thr	Thr	Ala	Thr	Ala	Ala	Phe	Glu	His	Gln	Asp	Val	Pro	Phe
	1410				,	1415					1420				

Glu Arg Val Val Thr Ala Leu Leu Pro Arg Ser Arg Asp Leu Ser Arg 425 1430 1435 1440

Asn Pro Leu Ala Gln Leu Thr Phe Ala Leu His Ser Gln Gln Asp Leu

1445 1450 1455

Gly Lys Phe Glu Leu Glu Gly Leu Val Ala Glu Pro Val Ser Asn Lys

1460 1465 1470

Val Tyr Thr Arg Phe Asp Val Glu Phe His Leu Phe Gln Glu Ala Gly

Arg Leu Ser Gly Asn Val Ala Phe Ala Ala Asp Leu Phe Lys Pro Glu

Thr Ile Ser Asn Val Val Ala Ile Phe Phe Gln Ile Leu Arg Gln Gly

Ile Arg Gln Pro Arg Thr Pro Ile Ala Val Leu Pro Leu Thr Asp Gly

Leu Ala Asp Leu Arg Ala Met Gly Leu Leu Glu Ile Glu Lys Ala Glu

Tyr Pro Arg Glu Ser Ser Val Val Asp Val Phe Arg Lys Gln Val Ala

Ala His Pro His Ala Phe Ala Val Val Asp Ser Ala Ser Arg Leu Thr

Tyr Ala Asp Leu Asp Arg Gln Ser Asp Gln Leu Ala Thr Trp Leu Gly

Arg Arg Asn Met Thr Ala Glu Thr Leu Val Gly Val Leu Ala Pro Arg

Ser Cys Gln Thr Val Val Ala Ile Leu Gly Ile Leu Lys Ala Asn Leu

Ala	Tyr Le	u Pro L	eu Asp	Val A	sn Cy	s Pro	Thr	Ala A	lrg L	eu Gl	n Thr
	1635	5		164	40			16	45		
Ile	Leu Ser	Thr L	eu Asn	Arg Hi	s Lys	: Leu	Val	Leu L	eu Gl	y Se	r Asn
ì	650	·		1655			1	660			
Ala	Thr Thr	Pro As	p Val	Gln II	e Pro	Asp	Val (Glu Le	eu Va	l Arg	: Ile
665			1670				675				1680
											-
Ser A	sp Ile	Leu As	p Arg	Pro Ile	e Asn	Gly (Gln A	la Ly	s Leu	ı Asn	Gly
		168	5		1	690				1695	
			•								
His T	hr Lys	Ser Asr	ı Gly 1	ſyr Ser	Lys	Pro A	sn G	ly Tyr	Thr	His	Leu
·	1	700			1705			•	1710		

Lys	Gly	Tyr	Ser	Asn	Leu	Asn	Gly	Tyr	Ser	Lys	Gln	Asn	Gly	Туг	Ala
		1715					1720					1725			
Gln	Leu	Asn	Gly	His	Arg	Glu	Arg	Asn	Asn	Tyr	Leu	Asp	Leu	Asn	Gly
	1730					1735					1740				
His	Ser	Leu	Leu	Asn	Gly	Asn	Ser	Asp	He	Thr	Thr	Ser	Gly	Pro	Ser
745					1750			•]	1755					1760
															-
Ala	Thr	Ser	Leu	Ala	Tyr	Val	Ile	Phe	Thr	Ser	Gly	Ser	Thr	Gly	Lys
			Ì	1765]	770				1	775	
				,											
Pro	Lys	Gly	Val	Met	Val	Glu	His	Arg	Ser	Ile	Ile	Arg	Leu	Ala	Lys
		l	780		•		1	785				1	790		

Lys Asn Arg I	le Ile Ser Arg I	Phe Pro Ser Va	ıl Ala Lys Va	ıl Ala His
1795	18	300	1805	
Leu Ser Asn Il	e Ala Phe Asp A	la Ala Thr Tr	p Glu Met Pho	e Ala Ala
1810	1815		1820	
Leu Leu Asn Gly	y Gly Thr Leu Va	l Cys Ile Asp	Tyr Met Thr	Thr Leu
825	1830	1835		1840
·				
Asp Ser Lys Thr	Leu Glu Ala Ala	a Phe Ala Arg	Glu Gln Ile	Asn Ala
	1845	1850	1	855

Ala Leu Leu Thr Pro Ala Leu Leu Lys Gln Cys Leu Ala Asn Ile Pro 1860 1865 1870 Thr Thr Leu Gly Arg Leu Ser Ala Leu Val Ile Gly Gly Asp Arg Leu

Asp Gly Gln Asp Ala Ile Ala Ala His Ala Leu Val Gly Ala Gly Val

Tyr Asn Ala Tyr Gly Pro Thr Glu Asn Gly Val Ile Ser Thr Ile Tyr

Asn Ile Thr Lys Asn Asp Ser Phe Ile Asn Gly Val Pro Ile Gly Cys

· Ala Ile Ser Asn Ser Gly Ala Tyr Ile Thr Asp Pro Asp Gln Gln Leu

Val Pro Pro Gly Val Met Gly Glu Leu Val Val Thr Gly Asp Gly Leu

Ala Arg Gly Tyr Thr Asp Pro Ala Leu Asp Ala Gly Arg Phe Val Gln

1980.

Ile Met Ile Asn Asp Lys Ala Val Arg Ala Tyr Arg Thr Gly Asp Arg

Ala Arg Tyr Arg Val Gly Asp Gly Gln Ile Glu Phe Phe Gly Arg Met

Asp Gln Gln Val Lys Ile Arg Gly His Arg Ile Glu Pro Ala Glu Val

2020 2025

Glu Arg Ala Ile Leu Asp Gln Asp Ser Ala Arg Asp Ala Val Val

Ile Arg His Gln Glu Gly Glu Glu Pro Glu Met Val Gly Phe Val Ala

Thr His Gly Asp His Ser Ala Glu Glu Glu Ala Asp Asp Gln Val

Glu Gly Trp Lys Asp Phe Phe Glu Ser Asn Thr Tyr Ala Asp Met Asp

Thr	Ile Gl	y Gli	n Ser	Ala	Ile	Gly	Asn	Asp	Phe	Thr	Gly	Trp	Thr	Sei
		2100)				2105					2110		
Met :	Tyr As	p Gly	Ser	Glu	Ile	Asn	Lys	Ala	Glu	Met	Gln	Glu	Trp	Leu
	211	5			2	120				2	2125			
		٠												
Asp A	lsp Thi	r Met	Arg	Thr	Leu	Leu	Asp	Gly	Gln	Ala.	Pro	Gly	His	Val
21	30			2	135				2	140				
Leu G	lu Ile	Gly	Thr	Gly S	Ser (Gly M	let '	Val	Leu 1	Phe <i>I</i>	Asn I	Leu (Glý <i>A</i>	Ma
145	•		2	150	٠			2	155				21	60
								*						

Gly Leu Gln Ser Tyr Val Gly Leu Glu Pro Ser Arg Ser Ala Ala Thr
2165 2170 2175

Phe Val Thr Lys Ala Ile Asn Ser Thr Pro Ala Leu Ala Gly Lys Ala 2180 2185 2190

Glu Val His Val Gly Thr Ala Thr Asp Ile Asn Arg Leu Arg Gly Leu 2195 2200 2205

Arg Pro Asp Leu Val Val Leu Asn Ser Val Val Gln Tyr Phe Pro Thr
2210 2215 2220

Pro Glu Tyr Leu Leu Glu Val Val Glu Ser Leu Val Arg Ile Pro Gly
225 2230 2235 2240

Val Lys Arg Val Val Phe Gly Asp Ile Arg Ser His Ala Thr Asn Arg

2245 2250 2255

His Phe Leu Ala Ala Arg Ala Leu His Ser Leu Gly Ser Lys Ala Thr 2260 2265 2270

Lys Asp Ala Ile Arg Gln Lys Met Thr Glu Met Glu Glu Arg Glu Glu

2275 2280 2285

Glu Leu Leu Val Asp Pro Ala Phe Phe Thr Ala Leu Leu Gln Gly Gln
2290 2295 2300

Leu Ala Asp Arg Ile Lys His Val Glu Ile Leu Pro Lys Asn Met Arg

305 2310 2315 2320

Ala Thr Asn Glu Leu Ser Ala Tyr Arg Tyr Thr Ala Val Ile His Val
2325 2330 2335

Arg Gly Pro Glu Glu Gln Ser Arg Pro Val Tyr Pro Ile Gln Val Asn

Asp Trp Ile Asp Phe Gln Ala Ser Arg Ile Asp Arg Arg Ala Leu Leu

Arg Leu Leu Gln Arg Ser Ala Asp Ala Ala Thr Val Ala Val Ser Asn

Ile Pro Tyr Ser Lys Thr Ile Val Glu Arg His Val Val Glu Ser Leu

Asp Asn Asn Asg Glu Asn Thr His Arg Ala Pro Asp Gly Ala Ala

Trp Ile Ser Ala Val Arg Ser Lys Ala Glu Arg Cys Thr Ser Leu Ser

Val Thr Asp Leu Val Gln Leu Gly Glu Glu Ala Gly Phe Arg Val Glu

Val Ser Ala Ala Arg Gin Trp Ser Gin Ser Gly Ala Leu Asp Ala Val

Phe His Arg Tyr Asn Leu Pro Thr Gln Ser Asn Ser Arg Val Leu Ile

Gln Phe Pro Thr Glu Asp Gly Gln Thr Arg Arg Ser Ala Thr Leu Thr

Asn Arg Pro Leu Gln Arg Leu Gln Ser Arg Arg Phe Ala Ser Gln Ile

Arg Glu Gln Leu Lys Ala Val Leu Pro Ser Tyr Met Ile Pro Ser Arg

Ile Val Val Ile Asp Gln Met Pro Leu Asn Ala Asn Gly Lys Val Asp

Arg Lys Glu Leu Thr Arg Arg Ala Gln Ile Ala Pro Lys Ser Gln Ala

Ala	Pro	Ala	Lys	Pro	Val	Lys	Gln	Val	Asp	Pro	Phe	Val	Asn	Leu	Glu
			,	2565					2570				:	2575	
Ala	Ile	Leu	Cys	Glu	Glu	Phe	Ala	Glu	Val	Leu	Gly	Met	Glu	Val	Gly
		4	2580				2	2585				4	2590		•
Val	Asn	Asp	His	Phe	Phe	Gln	Leu	Gly	Gly	His	Ser	Leu	Leu	Ala	Thr
	2	595				2	600				2	605			

Lys Leu Val Ala Arg Leu Ser Arg Arg Leu Asn Gly Arg Val Ser Val
2610 2615 2620

Arg Asp Val Phe Asp Gln Pro Val Ile Ser Asp Leu Ala Val Thr Leu 625 2630 2635 2640

Arg Gln Gly Leu Thr Leu Glu Asn Ala Ile Pro Ala Thr Pro Asp Ser 2645 2650 2655

Gly Tyr Trp Glu Gln Thr Met Ser Ala Pro Thr Thr Pro Ser Asp Asp

2660 2665 2670

Met Glu Ala Val Leu Cys Lys Glu Phe Ala Asp Val Leu Gly Val Glu

2675 2680 2685

Val Ser Ala Thr Asp Ser Phe Phe Asp Leu Gly Gly His Ser Leu Met
2690 2695 2700

Ala Thr Lys Leu Ala Ala Arg Ile Ser Arg Arg Leu Asp Val Pro Val 705 2710 2715 2720 Ser Ile Lys Asp Ile Phe Asp His Ser Val Pro Leu Asn Leu Ala Arg

Lys Ile Arg Leu Thr Gln Ala Lys Gly His Glu Ala Thr Asn Gly Val

Gln Ile Ala Asn Asp Ala Pro Phe Gln Leu Ile Ser Val Glu Asp Pro

Glu Ile Phe Val Gln Arg Glu Ile Ala Pro Gln Leu Gln Cys Ser Pro

Glu Thr Ile Leu Asp Val Tyr Pro Ala Thr Gln Met Gln Arg Val Phe

Leu Leu Asn Pro Val Thr Gly Lys Pro Arg Ser Pro Thr Pro Phe His

Ile Asp Phe Pro Pro Asp Ala Asp Cys Ala Ser Leu Met Arg Ala Cys

Ala Ser Leu Ala Lys His Phe Asp Ile Phe Arg Thr Val Phe Leu Glu

Ala Arg Gly Glu Leu Tyr Gln Val Val Leu Lys His Val Asp Val Pro

285.5

Ile Glu Met Leu Gln Thr Glu Glu Asn Ile Asn Ser Ala Thr Arg Ser

Phe Leu Asp Val Asp Ala Glu Lys Pro Ile Arg Leu Gly Gln Pro Leu

Ile Arg Ile Ala Ile Leu Glu Lys Pro Gly Ser Thr Leu Arg Val Ile

Leu Arg Leu Ser His Ala Leu Tyr Asp Gly Leu Ser Leu Glu His Ile

Leu His Ser Leu His Ile Leu Phe Phe Gly Gly Ser Leu Pro Pro

Pro Lys Phe Ala Gly Tyr Met Gln His Val Ala Ser Ser Arg Arg Glu

Gly Tyr Asp Phe Trp Arg Ser Val Leu Arg Asp Ser Ser Met Thr Val

Ile Lys Gly Asn Asn Asn Thr Thr Pro Pro Pro Pro Gln Gln Gln

Ser Thr Pro Ser Gly Ala His His Ala Ser Lys Val Val Thr Ile Pro

Thr Gln Ala Asn Thr Asp Ser Arg Ile Thr Arg Ala Thr Ile Phe Thr

INT ATA CYS	Ala Leu Met Le	u Ala Lys G	lu Asp Asn S	Ser Ser Asp Val
025	3030		3035	3040
Val Phe Gly A	Arg Thr Val Ser	Gly Arg Gl	n Gly Leu P	ro Leu Ala His
	3045	305	0	3055
Gln Asn Val I	le Gly Pro Cys	Leu Asn Glr	n Val Pro Ņa	ıl Arg Ala Arg
30	60	3065		3070
	÷.			
Gly Leu Asn Ar	g Gly Thr Thr	His His Arg	Glu Leu Le	u Arg Glu Met
3075	3	080	308	5
	·		·	•
Gln Glu Gln Ty	r Leu Asn Ser	Leu Ala Phe	Glu Thr Let	ı Gly Tyr Asp
3090	3095		3100	

Glu	He	Lys	Ala	His	Cys	Thr	Asp	Trp	Pro	Asp	Val	Pro	Ala	Thr	Ala
105					3110					3115					3120
				·											
Ser	Phe	Gly	Cys	Cys	Ile	Val	Tyr	Gln	Asn	Phe	Asp	Ser	His	Pro	Asp
				3125				;	3130				. 6	3135	
Ser	Arg	Val	Glu	Glu	Gln	Arg	Leu	Gln	Ile	Gly	Val	Leu	Ser	Arg	Asn
		ć	31,40					3145				ć	3150		
															٠
Tyr	Gļu	Ala	Ile	Asn	Glu	Gly	Leu	Val	His	Asp	Leu	Val	Ile	Ala	Gly
	3	3155				3	160			:	3	165			
				,											
Glu S	Ser	Glu	Pro	Asp	Glv	Asp	Asn	l.eu	Arg	Val	Thr	Val	Val	Ala	Asn

Arg Arg Leu Cys Asp Glu Glu Arg Leu Lys Arg Met Leu Glu Glu Leu
185 3190 3195 3200

Cys Gly Asn Ile Arg Ala Leu Ala Leu Val

3205

3210

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 3

tggacnwsna tgtaygaygg

- 20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

⟨220⟩

<223> Description of Artificial Sequence:synthetic DNA

` <400> 4

gtnggraart	aytgnacnac
------------	------------

20

<210> 5

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 5

gcggaattaa ccctcactaa agggaacgaa

<210> 6

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 6

gcgtaatacg actcactata gggcgaagaa

30

<210> 7

<211> 41

12	12>	DNA
\4	14/	レいか

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 7

agcatcggat cctaacaatg ggcgttgagc agcaagccct a

41

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 8

tttgcttcgt actcgggtcc t

21

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

` <223> Description of Artificial Sequence:synthetic DNA

<400> 9

gcatcgcgat actagagaag

20

<210> 10

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 10

agcatcgaat tcggatccct aaaccaacgc caaagcccga at

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 11

tgatatgctg gagcttccct

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthet.ic DNA

<400> 12

gcacaacctc tttccaggct

20

<210> 13

<211> 42

<212> DNA

<220>

<223> Description of Artificial Sequence:synthetic DNA

<400> 13

agcatcggat cctaacaatg tcaaacatgg caccactccc ta

42


[Brief description of the drawings]


[Figure 1]

Figure 1 shows a construction procedure of plasmid pABP/PFsyn.

[Figure 2]

Figure 2 schematically shows the SDS-PAGE result of the expression, in a gene-introduced strain, of the cyclic depsipeptide synthetase which is the translation product of the gene of the present invention.





[TTTLE OF DOCUMENT] ABSTRACT [ABSTRACT]

[OBJECT OF INVENTION]

To provide a method for producing a cyclic depsipeptide having anthelmintic activity, a cyclic depsipeptide synthetase gene capable of improving productivity of the substance PF1022 and a protein coding therefor, a recombinant vector comprising the gene, and a substance PF1022-producing microorganism and substance PF1022 into which the recombinant vector is introduced.

[MEANS FOR ATTAINING THE OBJECT]

A gene encoding a cyclic depsipeptide synthetase enhancing the biosynthesis of the substance PF1022 is isolated from a substance PF1022-producing microorganism. A recombinant vector is prepared by the substitution of the promoter and terminator of the gene with those of a foreign gene utilizable for expression augmentation, and then the recombinant vector is introduced into the substance PF 1022-producing microorganism, whereby the improvement in productivity of the substance PF 1022 was attained.

[SELECTED FIGURE]

None